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ABSTRACT 
Clinical studies suggest that postmenopausal women are at an increased risk for 
type 2 diabetes (T2D), and hormone replacement therapy can ameliorate this risk.  
Considerable clinical and experimental evidence exists demonstrating the ability of 
estrogen to modulate glucose metabolism in insulin responsive tissues such as the skeletal 
muscle and adipose tissue.  Specifically, previous studies suggest estrogen receptor α 
(ERα) is involved in estrogen-mediated regulation of metabolism and is critical for the 
maintenance of whole body insulin action.  However, very little is known regarding the 
mechanisms of action of ERα in insulin-responsive tissues.  
In addition, clinical evidence demonstrates that many women gain weight 
following menopause.  This increase in body weight is accompanied by an increase in 
abdominal adipose tissue, which greatly increases one’s risk for T2D.  These studies are 
supported by animal models of ovariectomy (OVX) in which removal of the ovaries 
results in increased total body weight and fat pad weight, which are ameliorated by 
estrogen treatment.  However, the mechanism of estrogen’s action remains unknown.  
 The purpose of our studies was to determine the effect of an obesity promoting 
high-fat diet (HFD) on skeletal muscle and adipose tissue estrogen receptor regulation 
and glucose metabolism in female rats with and without OVX.  Furthermore we 
determined the effects of specific ERα activation on skeletal muscle glucose metabolism 
and adipose tissue triglyceride regulation.  
 We found that a HFD decreased whole body glucose intolerance, without 
decreasing insulin-stimulated skeletal muscle glucose uptake, as previously found in male 
 iv 
animal models.  In female animal models, the HFD-induced decrease in whole body 
glucose tolerance likely occurred from alterations in the adipose tissue such as decreased 
glucose transporter 4 and ERα protein levels and increased activation of stress kinases.  
Furthermore, specific activation of ERα increased glucose uptake and potentiated 
the insulin signaling pathway in skeletal muscle.  In addition, specific ERα activation 
decreased body weight and fat pad weight, decreased proteins involved in lipogenesis, 
and increased proteins involved in lipolysis.   
This information suggests novel roles of ERα in skeletal muscle glucose 
metabolism and adipocyte regulation and may help explain the metabolic differences 
between premenopausal and postmenopausal women. 
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INTRODUCTION 
 
 
Obesity and metabolic syndrome. 
 
Throughout recent history, epidemic rates of obesity emerged as a result of 
changes in our environment and lifestyle.  The 2007-2008 National Health and Nutrition 
Examination Survey (NHANES) determined that obesity manifests 33.8% of the adult 
U.S. population (Flegal et al. 2010).  The alarming obesity rate raises concern, as obesity 
greatly increases one’s risk for type 2 diabetes (T2D), hypertension, and dyslipidemia, all 
of which belong to a constellation of metabolic abnormalities termed “metabolic 
syndrome” (Zimmet et al. 2005).  
The origin of metabolic syndrome began almost 90 years ago when a physician 
noted that hyperglycemia and hypertension often occurred in parallel (Kylin 1923).  The 
metabolic syndrome expanded its characteristics in 1979 when obesity, particularly upper 
body or central obesity, was also found to be associated with hyperglycemia and 
hypertension (Vague 1956).  In 1988, Reaven brought to light the importance of 
understanding metabolic syndrome, or syndrome X, and spurred research focused on this 
cluster of metabolic abnormalities which increases one’s risk of cardiovascular disease 
(Reaven 1988).   
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The criteria defining metabolic syndrome evolved over the past 20 years with 
reputable organizations such as the World Health Organization, the European Group for 
Studying Insulin Resistance, and the National Cholesterol Education Program all setting 
guidelines for diagnosing metabolic syndrome (NCEP 2001; Einhorn et al. 2003; Alberti 
et al. 2005).  These guidelines include four common criteria: 1) hyperglycemia or T2D, 
2) obesity, 3) dyslipidemia, and 4) hypertension.  The differences in the definition of 
metabolic syndrome include putting importance on one of the criteria and detection 
method and definition of the criteria.  The differences in criteria led to confusion in the 
clinical and research field and make comparisons among various research studies 
difficult.  Therefore, these problems encouraged the International Diabetes Federation 
(IDF) to introduce a standardized definition of metabolic syndrome (Zimmet et al. 2005).  
In 2005, the IDF released a worldwide definition of metabolic syndrome which places an 
importance on central obesity.  People are diagnosed with metabolic syndrome if they 
have central obesity and two of the following four criteria: 1) raised triglycerides, 2) 
reduced HDL-cholesterol, 3) raised blood pressure, and 4) raised fasting plasma glucose.   
Central obesity prevailed as the essential component of metabolic syndrome as it 
independently increases one’s risk for cardiovascular disease and the four criteria of 
metabolic syndrome (Fujioka et al. 1987; Despres et al. 1989; Seidell et al. 1990; 
Fujimoto et al. 1994; Kissebah and Krakower 1994; Boyko et al. 1995; Carey et al. 1997; 
Zimmet et al. 2001; Hu et al. 2004), and it is the number one risk factor for developing 
T2D (Kissebah and Peiris 1989; Chan et al. 1994; Despres 2006).  Of the four criteria for 
metabolic syndrome, raised fasting plasma glucose, or T2D, places the greatest burden on 
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the U.S.  According to the Centers for Disease Control and Prevention (CDC), T2D is the 
7th leading cause of death in the U.S., and it is also one of the main causes of mortality 
and morbidity worldwide (Saltiel and Kahn 2001).  In 2008, the CDC released a special 
press bulletin stating that the prevalence of diagnosed T2D in the U.S. increased by 14% 
from 2007 to 2008.  The current diabetic population reached 24 million in 2008, which is 
nearly 8% of the U.S. population.  In addition to these diagnosed cases of T2D, the 
number of people with undiagnosed T2D and those at risk for T2D totals an additional 57 
million people.  As such, research focused on the pathogenesis of obesity and T2D will 
give great insight to this widespread epidemic.  Furthermore, the development of new 
treatment methods has the potential to greatly reduce mortality and morbidity on a global 
scale.  
 
 
Diabetes.  
  
The Merriam-Webster dictionary defines diabetes as “excretion of excessive 
amounts of urine”. Diabetes as a whole encompasses various conditions which are 
divided into two sub-categories: mellitus and insipidus.  Diabetes insipidus results from a 
deficiency in antidiuretic hormone or a resistance to antidiuretic hormone in the kidneys, 
both of which result in excessive urination.  However, the term “diabetes” often refers to 
diabetes mellitus which results from a deficiency in insulin or a resistance to insulin.  
Diabetes mellitus includes two main sub-groups: type 1 diabetes (T1D) and T2D.  T1D 
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accounts for 5-10% of all diabetes mellitus cases and results from a deficiency in insulin 
(CDC 2010).  Insulin deficiency is thought to result from an autoimmune response which 
destroys the insulin-secreting β cells in the pancreas (Knip and Siljander 2008).  
Diagnosis of T1D commonly occurred in children, and therefore, was formerly called 
juvenile onset diabetes.  T1D also requires treatment of exogenous insulin, and therefore, 
was formerly called insulin dependent diabetes (Cohen and Shaw 2007).  However, the 
terms juvenile onset and insulin dependent diabetes are no longer used due to the 
inaccuracy of the terms.  Today, adults are also diagnosed with T1D, and the alarming 
obesity rate in children has greatly increased the incidence of T2D in children (Klein et 
al. 2004).  Furthermore, while those with T1D are insulin dependent, people with T2D 
may also become insulin dependent. 
T2D accounts for 90-95% of all cases of diabetes mellitus and results from insulin 
resistance (CDC 2010).  In the early stages of T2D, the pancreatic β cells produce insulin, 
but tissues are non-responsive to the insulin.  As the pancreas tries to compensate by 
producing higher levels of insulin, β cell failure and insulin deficiency ultimately results 
(Weir and Bonner-Weir 2007).  This insulin deficiency leads to a requirement of 
exogenous insulin to treat the disease (Prentki and Nolan 2006).  Thus, as T2D was 
formerly known as non-insulin dependent diabetes, this term is no longer used.  
Diagnosis of T2D commonly occurred in adults, and therefore, was also called adult 
onset diabetes.  However, as mentioned previously, the increase in childhood obesity and 
T2D makes this term invalid.   
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While T1D and T2D make up the most of the diabetic population, other forms of 
diabetes also exist.  Gestational diabetes develops in 2-5% of all pregnancy and results in 
insulin resistance (CDC 2010).  Gestational diabetes disappears after the pregnancy, 
although women who have gestational diabetes have up to a 70% greater risk for 
developing T2D later in life (Kim et al. 2002; Ben-Haroush et al. 2004).  Other types of 
diabetes can result from specific genetic syndromes, surgery, drugs, malnutrition, 
infections, and other illnesses and account for 1-2% of all diagnosed cases of diabetes 
(CDC 2010). 
 
 
Diagnosis of Diabetes. 
 
The American Diabetes Association (ADA) set guidelines for diagnosing diabetes 
(ADA 2010a).  Two commonly used tests to diagnose diabetes include the fasting plasma 
glucose (FPG) test and the oral glucose tolerance test (OGTT).  The FPG determines one 
to be diabetic if fasting glucose levels are > 126 mg/dL.  Normal FPG levels are below 
100 mg/dL, and individuals with FPG levels between 100 mg/dL and 125 mg/dL are 
considered pre-diabetic.  When using the OGTT, patients with blood glucose levels > 200 
mg/dL two hours after consuming a glucose load are considered diabetic.  Blood glucose 
levels should be < 140 mg/dL two hours after consuming a glucose load, and individuals 
with blood glucose levels between 140 mg/dL and 199 mg/dL are considered pre-
diabetic.  In January 2010 the ADA established an additional parameter for diagnosing 
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diabetes (ADA 2010b).  Measuring glycated hemoglobin A1c (HbA1c) now serves as an 
additional means to diagnose diabetes.  HbA1c indicates a person’s average blood 
glucose over the past three months and is commonly used to assess how patients are 
managing their diabetes.  A person without diabetes should have a HbA1c less than 5%.  
Under the new guidelines, a HbA1c between 5.7-6.4% indicates pre-diabetes and > 6.5% 
indicates diabetes.  The ADA recommends diabetics to keep their HbA1c below 7% 
(ADA 2010a).   
   
 
Sex differences and T2D. 
 
Differences exist between females and males with respect to the prevalence of 
T2D in human studies and inducing T2D in animal models.  The prevalence of T2D is 
greater in males compared to females in developed nations such as Australia and Sweden 
(Welborn et al. 1989; Andersson et al. 1991).  While a 2006 report from NHANES 
concluded that the prevalence of diagnosed T2D in the U.S. is similar by sex, the 
prevalence of undiagnosed diabetes and pre-diabetes is greater in males (Cowie et al. 
2006).  In addition, numerous human studies show greater insulin sensitivity in females 
(Nuutila et al. 1995; Donahue et al. 1997; Nilsson et al. 2000; Borissova et al. 2005; 
Vistisen et al. 2008; Hoeg et al. 2009; Karakelides et al. 2010). 
In human studies, measuring whole body insulin sensitivity by the euglycemic-
hyperinsulinemic clamp remains the gold standard (DeFronzo et al. 1979; Angioni et al. 
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2008).  The euglycemic-hyperinsulinemic clamp involves the simultaneous infusion of 
glucose and insulin into the bloodstream with the purpose of maintaining constant blood 
glucose levels.  During the process, the glucose infusion rate is measured.  A higher 
glucose infusion rate (to keep the blood glucose levels constant) signifies greater glucose 
disposal into insulin-responsive tissues, and hence, greater insulin sensitivity.  Numerous 
studies using the euglycemic-hyperinsulinemic clamp in healthy weight subjects 
demonstrate higher glucose infusion rates in pre-menopausal women than in age-matched 
men, which indicate greater insulin sensitivity in women (Nuutila et al. 1995; Nilsson et 
al. 2000; Borissova et al. 2005; Hoeg et al. 2009; Karakelides et al. 2010).  The greater 
insulin sensitivity in women was present despite a greater number of total insulin 
receptors, high-affinity insulin receptors, and percent of receptors bound to insulin in 
males (Borissova et al. 2005).  Some studies in these pre-menopausal women also 
demonstrate lower fasting glucose (Nilsson et al. 2000; Karakelides et al. 2010) and 
lower insulin secretion during an OGTT than men (Donahue et al. 1997), which suggests 
better glucose control in women.  However, fasting insulin levels do not appear to be 
different between men and women (Nilsson et al. 2000).  The increased whole body 
insulin sensitivity in women can be explained by greater glucose uptake into skeletal 
muscle (Nuutila et al. 1995; Hoeg et al. 2009). Nuutila et al. demonstrated a 47% greater 
rate of skeletal muscle glucose uptake in women during the euglycemic-hyperinsulinemic 
clamp, with rates of glucose uptake in cardiac muscle similar between men and women 
(Nuutila et al. 1995).   
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In addition to healthy weight women having greater insulin sensitivity than men, 
obese pre-menopausal women also demonstrate lower glucose infusion rates during the 
euglycemic-hyperinsulinemic clamp compared to obese men, indicating greater insulin 
sensitivity in obese women.  In contrast to healthy weight subjects, no difference in 
fasting glucose is present between obese women and men (Vistisen et al. 2008).   
In contrast to these studies showing greater insulin sensitivity in women, no 
difference in insulin sensitivity was present between healthy weight pre-menopausal 
women and men in dexamethasone-induced insulin resistance.  Dexamethasone is a 
glucocorticoid analogue that induces insulin resistance by increasing plasma free fatty 
acids (Venkatesan et al. 1987; Guillaume-Gentil et al. 1993; Tappy et al. 1994) and 
decreasing skeletal muscle glucose uptake (Carter-Su and Okamoto 1985). 
Numerous animal models exist to study T2D, with the high-fat feeding model 
being one of the most commonly used.  The high-fat feeding model assess changes in 
adiposity, glucose metabolism, fatty acid regulation, and numerous other cellular 
mechanisms related to the pathogenesis and development of insulin resistance, glucose 
intolerance, and T2D.  Most previous studies show that female rodents are less 
susceptible to T2D as a result of high-fat feeding than males (Corsetti et al. 2000; 
Coatmellec-Taglioni et al. 2002; Yakar et al. 2006; Hong et al. 2009).  A 10 week HFD 
(50% kcal from fat) in male Sprague Dawley rats resulted in a significant increase in 
body weight, while the same HFD did not result in increased body weight in female 
animals (Coatmellec-Taglioni et al. 2002).  An additional study showed that 20 weeks of 
high-fat feeding in mice (35% kcal from fat) resulted in a significant increase in body 
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weight and adipose tissue weight in both male and females, although the effect of the 
HFD was greater in males (Hong et al. 2009).  However, not all studies show differences 
in susceptibility to T2D between male and female animals fed a high-fat diet (HFD) 
(Catala-Niell et al. 2008; Gomez-Perez et al. 2008).  In contrast to the studies showing 
females rodents being less susceptible to high-fat feeding, 14 weeks of a HFD (30% kcal 
from fat) resulted in the same effect in female and male Wistar rats: the HFD increased 
body weight in 15 month old animals (Gomez-Perez et al. 2008), but it did not increase 
body weight in 2 month old animals (Catala-Niell et al. 2008).  Variability in results from 
HFD studies stem from differences in assessed outcome variables, the duration and 
composition of the HFD, and the species/strain used in the study, to name a few. 
 While weight gain in response to a HFD may be a very important predictor for 
susceptibility to T2D, specific measurements of insulin resistance and glucose intolerance 
between female and male animals would better characterize these differences.  In 2006, 
Yakar et al. found that a 10 week HFD (35% kcal from fat) significantly increased the 
body weight and percent body fat in both female and male mice (Yakar et al. 2006).  
However, the male animals also exhibited increased serum glucose and insulin levels, 
insulin resistance as measured by an insulin tolerance test, and impaired glucose 
tolerance as measured by a glucose tolerance test.  Female animals did not display insulin 
resistance and impaired glucose tolerance.  As adiposity is such an important predictor of 
T2D, the dimorphism between the sexes in susceptibility of HFD-induced T2D may be 
due to differences in body fat storage between males and females.  
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Sex differences in body fat distribution. 
  
Differences in body fat storage exist between men and women.  Men tend to store 
more of their fat in the abdominal area, and pre-menopausal women tend to store most of 
their fat in the gluteofemoral area (Vague 1956; Kvist et al. 1988; Lemieux et al. 2003).  
However, menopause brings about changes in fat storage in women.  After menopause, 
the amount of total body fat and abdominal fat increases (Svendsen et al. 1995; Toth et al. 
2000; Sites et al. 2002).  As abdominal fat is the number one risk factor for developing 
T2D (Kissebah and Peiris 1989; Chan et al. 1994; Despres 2006), the difference in fat 
storage between pre-menopausal women and men may explain the protective effect 
women have over men against developing T2D.   
In fact, women with predominately upper body obesity are more likely to have 
impaired glucose tolerance than women with predominately lower body obesity 
(Kissebah et al. 1982).  In addition, decreased insulin sensitivity was highly associated 
with increased visceral adipose tissue in obese post-menopausal women.  Obese post-
menopausal women with greater amounts of visceral adipose tissue were more likely to 
have decreased insulin sensitivity (Brochu et al. 2000; Brochu et al. 2001).  These studies 
suggest that the presence of abdominal fat in women diminishes the protective effect 
women have over men against developing T2D.  However, a study comparing non-obese 
pre- and post-menopausal women demonstrated that the increase in abdominal fat after 
menopause did not result in increased fasting insulin and glucose levels or a lower 
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glucose infusion rate during the euglycemic-hyperinsulinemic clamp (Sites et al. 2002).  
Thus, while abdominal fat may indeed be the number one risk factor for developing T2D, 
reproductive hormones may also play a role in glucose regulation. 
  
 
Insulin sensitivity during the menstrual cycle.    
 
Numerous studies demonstrate changes in insulin sensitivity during the menstrual 
cycle in females (Jarrett and Graver 1968; Valdes and Elkind-Hirsch 1991; Widom et al. 
1992; Escalante Pulido and Alpizar Salazar 1999), although additional studies 
demonstrate no differences (Yki-Jarvinen 1984; Toth et al. 1987; Diamond et al. 1993; 
Trout et al. 2007; Bingley et al. 2008).  The intravenous glucose tolerance test (IVGTT) 
has been used to assess insulin sensitivity in various populations of women throughout 
their menstrual cycle.  When conducting an IVGTT during the follicular and luteal phase 
in healthy, normal cycling women, insulin sensitivity was decreased during the luteal 
phase (Valdes and Elkind-Hirsch 1991; Escalante Pulido and Alpizar Salazar 1999) or 
showed no differences (Bingley et al. 2008).  In addition, decreased insulin sensitivity 
during the luteal phase has also been shown in patients with type 1 diabetes (Widom et al. 
1992), although another study demonstrated no difference in this population (Trout et al. 
2007).  When using the euglycemic-hyperinsulinemic clamp to assess insulin sensitivity, 
studies demonstrate no differences in insulin sensitivity throughout the menstrual cycle 
(Yki-Jarvinen 1984; Toth et al. 1987; Diamond et al. 1993).  Although the discrepancies 
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among these results suggest that more studies are needed to assess changes in insulin 
sensitivity during the menstrual cycle, these studies also suggest that reproductive 
hormones may be involved in glucose regulation. 
While the inconclusiveness of the previous studies may be due to the low sample 
size, other researchers have stratified their study population to decipher the reason why 
some women show differences in insulin sensitivity during their menstrual cycle and 
others do not.  Gonzales-Ortiz et al. found that healthy women without a family history if 
T2D had decreased insulin sensitivity during the luteal phase, but healthy women with a 
family history of T2D did not (Gonzalez-Ortiz et al. 1998).  Importantly, the changes in 
insulin sensitivity during the menstrual cycle has been attributed to changes in 17β-
estradiol (E2) levels, and not other reproductive hormones such as progesterone, 
testosterone, dihydrotestosterone, androstenedione, luteinizing hormone, follicular-
stimulating hormone, or prolactin (Widom et al. 1992). 
 
 
E2 and glucose regulation in postmenopausal women.   
 
Postmenopausal women incur a greater risk of T2D compared to premenopausal 
women (Lindheim et al. 1994; Lynch et al. 2002).  Postmenopausal women have higher 
fasting blood glucose and insulin compared to age- and body mass index-matched 
premenopausal women (Lynch et al. 2002).  Lindheim et al. also demonstrates decreased 
insulin sensitivity and glucose tolerance in healthy postmenopausal women compared to 
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premenopausal women (Lindheim et al. 1994).  Additional studies show benefits of 
combined E2/progestin hormone replacement therapy (HRT) (Andersson et al. 1997; 
Espeland et al. 1998; Kanaya et al. 2003; Margolis et al. 2004; Gower et al. 2006). The 
Heart and Estrogen/Progestin Replacement Study (HERS) and the Women’s Health 
Initiative Hormone Trial (WHI) were two large-scale, national studies with over 2,500 
and 16,000 subjects, respectively, which assessed the overall potential benefits and risks 
of HRT, including risk factors for T2D.  The HERS found that the incidence of insulin 
resistance in healthy, postmenopausal women on HRT for one year was 35% less 
compared to postmenopausal women not on HRT (Kanaya et al. 2003).  The WHI 
demonstrates that fasting glucose and insulin levels also decreased in postmenopausal 
women after one year of HRT (Margolis et al. 2004).  (Lindheim et al. 1994; Lobo et al. 
1994; Colacurci et al. 1998).  In addition, a double blind study by Andersson et al. found 
that E2 replacement for 3 months in postmenopausal women with T2D improved their 
glucose homeostasis versus women with T2D taking a placebo as measured by 
euglycemic-hyperinsulinemic clamp (Andersson et al. 1997).  Of note, a recent study by 
Gower et al. randomized early postmenopausal women to HRT or placebo for two years.  
As menopause is closely associated with an increase in abdominal fat, this study assessed 
the independent effect of menopause on insulin sensitivity and found that HRT, even in 
the presence of increased abdominal fat, increased insulin sensitivity at the end of the two 
year study (Gower et al. 2006).    
Studies demonstrating positive effects on glucose regulation with the use of 
combined HRT lead to questions as to whether E2, progestin, or the combination of the 
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two hormones provides the benefits.  Studies investigating this show that E2 alone 
provides the greatest benefit (Cagnacci et al. 1992; Lindheim et al. 1994; Lobo et al. 
1994; Cagnacci et al. 1997; Colacurci et al. 1998; Espeland et al. 1998), and this response 
may be attenuated with the combination of E2 and progestin.  
While E2 replacement benefits postmenopausal women in terms of glucose 
regulation, the overall risks may outweigh the benefits.  The WHI sought to determine the 
overall benefits and risks of HRT in postmenopausal women to serve as a guideline for 
clinical practice.  The trial ended early due to the increased risk of severe health 
complications including breast cancer, thrombosis, and coronary heart disease in the HRT 
treated group (Nelson et al. 2002).  Study investigators concluded that the overall risks of 
HRT exceeded the benefits.  Therefore, understanding the mechanism by which E2 may 
positively modulate glucose metabolism may provide important information for 
developing new treatment methods against T2D without the risks of HRT. 
 
 
Ovariectomy in rodents models the postmenopausal state. 
 
While clinical studies demonstrate the beneficial effect of E2 on glucose 
metabolism, the molecular mechanisms of E2 remain largely unknown.  The use of rodent 
models has greatly contributed to the knowledge of cellular and molecular effects of E2 
on glucose metabolism.  Ovariectomy (OVX) in rodents involves bi-lateral removal of 
the ovaries and models the postmenopausal state in humans.   
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Like postmenopausal women, OVX in rodents results in total body weight gain 
(Yakar et al. 2006; Nunez et al. 2007; Nunez et al. 2008; Hong et al. 2009) total body fat 
gain (Nunez et al. 2007), and a HFD combined with OVX further increases weight gain 
in female rodents (Yakar et al. 2006; Nunez et al. 2007; Nunez et al. 2008).  The 
decreased susceptibility to T2D that females demonstrate over males also diminishes 
after rats undergo OVX (Hong et al. 2009) or become acyclic (Gomez-Perez et al. 2008).  
OVX has also been shown to impair insulin sensitivity and glucose metabolism in 
animal models (Kumagai et al. 1993; Wagner et al. 1998; Yakar et al. 2006).  Ten weeks 
post OVX in mice resulted in glucose intolerance as measured by GTT (Yakar et al. 
2006).  Kumagai et al. also found that rats ovariectomized for six months developed 
whole body insulin resistance and demonstrated decreased glucose uptake in skeletal 
muscle.  E2 replacement alone or in combination with progesterone ameliorated the 
insulin resistance, but progesterone alone had no effect (Kumagai et al. 1993).  These 
studies demonstrate that OVX in rodents results in similar phenotypes and glucose 
metabolism seen in postmenopausal women and can serve as a model to study the cellular 
and molecular effects of E2 on glucose metabolism. 
 
 
Skeletal Muscle. 
  
The skeletal muscle is highly metabolic and accounts for 75% of the glucose 
uptake that occurs in the body (Bjornholm and Zierath 2005).  Therefore, the capability 
17 
 
for proper glucose disposal into the skeletal muscle serves an important metabolic 
function.  While obesity leads to whole body insulin resistance, skeletal muscle insulin 
resistance often serves as an earlier indicator for the impending whole body insulin 
resistance and T2D.   
The mammalian skeletal muscle is primarily made up of two different fiber types: 
slow-twitch and fast-twitch (Delp and Duan 1996).  Slow-twitch fibers contain more 
mitochondria and myoglobin and have high oxidative capacity (Guyton and Hall 2006).  
Therefore, they are also called oxidative, red (due to the mitochondria-inducing red 
appearance), or type I fibers.  Fast-twitch fibers contain fewer mitochondria and 
myoglobin and have high glycolytic capacity.  Therefore, they are also referred to as 
glycolytic, white, or type II fibers.  Variations exist within fast-twitch fibers.  These 
fibers are further classified by their oxidative/glycolytic properties.  Type IIa fibers are 
both oxidative and glycolytic and are considered intermediate fast-twitch fibers.  Type IIb 
fibers are non-oxidative/glycolytic and are not typically expressed in humans 
(Spangenburg and Booth 2003).  Type IId/x fibers contain oxidative and glycolytic 
properties that are between type IIa and type IIb fibers (Delp and Duan 1996).  Certain rat 
muscles may primarily express either slow- or fast-twitch fibers and, therefore, provide a 
good model for studying fiber type-specific responses to a physiological state.  For 
example, the soleus muscle in the hind limb consists predominantly of slow-twitch fibers 
(84% type I, 16% type IIa, 0% type IIb), and the extensor digitorum longus (EDL) 
muscle in the hind limb consists predominantly of fast-twitch fibers (3% type I, 57% type 
IIa, and 40% type IIb) (Ariano et al. 1973).   
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Slow- and fast-twitch fibers possess different insulin signaling characteristics.  
Slow-twitch fibers are more responsive to insulin as they exhibit a greater insulin binding 
capacity, increased activation of insulin signaling intermediates, and greater insulin-
simulated glucose uptake compared to fast-twitch fibers (Bonen et al. 1981; James et al. 
1985a; Ploug et al. 1987; Song et al. 1999).  In contrast, exercise-induced glucose uptake 
may (James et al. 1985b) or may not (Ploug et al. 1987) be greater in slow-twitch fibers.  
Studies also suggest that glucose transporter 4 (GLUT4), the primary glucose transporter 
in skeletal muscle, levels are greater in slow-twitch fibers (type I), although GLUT4 may 
actually be greater in both type I and type IIa fibers compared to type IIb fibers (James et 
al. 1989; Henriksen et al. 1990).  In addition, obese people have fewer type I fibers and 
greater type II fibers than lean people (Hickey et al. 1995).  Therefore, estrogen’s ability 
to alter glucose metabolism in the skeletal muscle may also depend on fiber type, and 
studying both slow- and fast-twitch muscle fibers is important. 
 
 
Adipose tissue.  
 
In mammals, two distinct types of adipose tissue exist.  White adipose tissue is the 
primary site for storing lipids for energy, and brown adipose tissue specializes in 
thermogenesis as it generates heat through mitochondrial uncoupling of lipid oxidation.  
Adipocytes form from mesenchymal stem cells during cellular differentiation.  While 
white adipose tissue derives from vascular cells, brown adipocytes arise from myogenic 
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precursors, thus giving each adipose tissue type its distinct properties and characteristics 
(reviewed in (Laharrague and Casteilla 2010).  Excessive stores of white adipose tissue 
contribute to many disorders associated with metabolic syndrome, including T2D.  
Therefore, the focus on white adipose tissue deserves further attention. 
White adipose tissue is present in the body in several subcutaneous and visceral 
areas. The tissue depots contain various cell types including adipocytes, preadipocytes, 
fibroblasts, endothelial cells, and multipotent stem cells which are able to differentiate 
into several cell types.  Mature adipocytes account for one third of the cell population and 
can expand to accommodate lipid storage (reviewed in (Armani et al. 2010).  In response 
to excess energy intake, expansion and accumulation of visceral fat occurs most notably 
and is linked to the development of metabolic disorders such as insulin resistance (Fox et 
al. 2007; Lee et al. 2010).  Accumulation of subcutaneous adipose tissue occurs less in 
response to excess energy intake and is not as highly associated with metabolic disorders 
(Gillum 1987; Kissebah and Krakower 1994).  In addition, Macotela et al. demonstrate 
increased insulin sensitivity in perigonadal adipose tissue (in the viscera) in female mice 
compared to male mice (Macotela et al. 2009), and this fat depot also has higher lipolytic 
capacity in females than in males (Pujol et al. 2003).  This data suggests that estrogen’s 
involvement in adipose tissue metabolic regulation may preferentially occur in the 
perigonadal depot. 
In addition to white adipose tissue functioning as a storage site for lipids, it also 
functions as an endocrine organ by secreting hormones.  These hormones are known as 
adipokines, and they regulate and integrate metabolic functions such as energy balance, 
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food intake and appetite, insulin sensitivity, blood pressure, and reproduction (Caprio et 
al. 2001).  Dysfunctional secretion of adipokines and free fatty acids, combined with 
dysregulated disposal of glucose and lipids, contributes to the development of many 
metabolic disorders (Rosen and Spiegelman 2006; Lefterova and Lazar 2009).  In 
addition, these alterations are associated with visceral fat accumulation (Berg and Scherer 
2005; Wildman et al. 2008). 
 
 
The function of the pancreas and insulin biosynthesis. 
  
The pancreas performs both exocrine and endocrine functions, both of which 
pertain to nutrient utilization.  The pancreas is made up of a variety of cells grouped into 
two major tissues: acini cells and islets of Langerhans.  The acini cells perform the 
exocrine function of the pancreas by secreting digestive juices into duodenum.  The cells 
in the islets of Langerhans perform the endocrine function and secrete hormones into the 
blood.  The beta cells are the most prevalent cell in the islets, making up 60% of the total 
cells.   
The beta cells synthesize and release insulin, which plays a key role in 
maintenance of whole body metabolism, and especially glucose metabolism.  Insulin is a 
protein containing two polypeptide chains linked together by disulfide bonds.  
Translation of insulin mRNA in the beta cells first results in formation of pre-proinsulin, 
which is cleaved into proinsulin.  C-peptide is then cleaved from proinsulin to form the 
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mature insulin.  Intracellular storage vesicles contain insulin and C-peptide until its 
signaled release (Halban 1994).  Glucose entry into the beta cells signals the release of 
insulin.  Glucose enters the beta cells via diffusion through the glucose transporter 
(GLUT) 2.  Increased production of ATP from the glucose inhibits the membrane 
ATP/K+ pumps, resulting in increased intracellular K+ levels.  The increased K+ level 
depolarizes the cell, resulting in opening of voltage-gated calcium channels.  The 
increased intracellular calcium signals fusion of the insulin storage vesicles with the 
membrane which releases insulin into the blood stream (Guyton and Hall 2006). 
Other cells reside in the islets of Langerhans in addition to beta cells, with the 
most prevalent being: 1) alpha cells which account for 25% of the cells in the islets and 
release glucagon; 2) delta cells which account for 10% of the cells in the islets and 
release somatostatin; and 3) the PP cells which account for 5% of the cells in the islets 
and secrete pancreatic poly peptide (Guyton and Hall 2006).  
 
 
Metabolic functions of insulin and insulin signaling pathways. 
 
 After the release of insulin into the blood stream, insulin binds to membrane 
insulin receptors in insulin responsive tissues such as the liver, adipose tissue, and 
skeletal muscle.  Insulin is most important for the regulation of glucose metabolism in 
these tissues.  In the liver, insulin inhibits gluconeogenesis by inhibiting 
phosphoenolpyruvate carboxykinase (Barthel and Schmoll 2003).  As mediated by 
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insulin, the skeletal muscle and adipose tissue are responsible for 75% (Bjornholm and 
Zierath 2005) and 10% (Klip et al. 1990), respectively, of the glucose disposal that occurs 
in the body.  In this manner, insulin maintains circulating glucose levels between 80 and 
100 mg/dL (Saltiel and Kahn 2001).   
 Insulin activates many cellular signaling cascades.  Two of the main signaling 
pathways which result in increased glucose disposal into the skeletal muscle and adipose 
tissue include the insulin receptor substrate (IRS)/phosphatidylinositol 3 kinase (PI3K) 
and Cbl/Cbl associated protein (CAP) pathways, which will be detailed here.   
 The IRS/PI3K pathway begins with the binding of insulin to the insulin receptor 
(IR) which resides in the cell membrane (Figure 1).  The IR is a dimeric tyrosine kinase 
receptor, and binding of insulin results in autophosphorylation on tyrosine residues 
(Taniguchi et al. 2006).  Phosphorylation of the IR results in recruitment and 
phosphorylation of IRS proteins.  There are six isoforms of the IRS proteins (IRS1-6) 
(Cai et al. 2003), and IRS-1 is the predominant isoform in skeletal muscle (Araki et al. 
1994).  All of the IRS proteins contain pleckstrin homology (PH) domains and 
phosphotyrosine binding domains which lead to recruitment of IRS to the IR.  The IRS 
proteins contain approximately 20 tyrosine phosphorylation sites located at the C 
terminus and center of the protein (Gual et al. 2005) which are phosphorylated by the 
activated IR.  Phosphorylated IRS proteins are capable of binding molecules containing 
Src-homology-2 domains, including PI3K.  PI3K then catalyzes the formation of 
phosphatidylinositol triphosphate (PIP3), which binds to and activates proteins containing 
the PH domain including phosphoinositide-dependent protein kinase-1 (PDK1).  
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Activation of PDK1 results in activation of Akt/PKB via phosphorylation on thronine 308 
and serine 473 (Alessi et al. 1997; Sarbassov et al. 2005).  Subsequently, Akt substrates 
of 160 kDa are activated, including TBC1D1 and TBC1D4 (also known as AS160) (Kane 
et al. 2002; Sano et al. 2003; Gonzalez and McGraw 2006; Taylor et al. 2008; Peck et al. 
2009).  While previous research only implicated TBC1D4 as a downstream target of Akt 
(hence the name Akt substrate 160 (AS160)), a newly discovered Akt substrate of 160 
kDa (TBC1D1) was also found be activated downstream of Akt (Taylor et al. 2008; Peck 
et al. 2009).  TBC1D1 and TBC1D4 are paralogs with sequences that are 47% identical 
(Roach et al. 2007).  Both substrates contain Rab-GTPase-activating protein (GAP) 
domains (Miinea et al. 2005; Peck et al. 2009).  Activation of TBC1D1 and TBC1D4 
suppresses the GAP activity, which elevates the active GTP form of Rab proteins.  The 
activated Rab proteins are involved in the cytoskeletal reorganization responsible for 
GLUT4 translocation to the plasma membrane (Sano et al. 2003; Sakamoto and Holman 
2008; Zaid et al. 2008).   
24 
 
 
   
IR 
 
IRS-1 
 
 PI3K 
 Akt 
 
  
GLUT4 
extracellular 
intracellular 
Insulin 
PIP2 PIP3 
PDK1 
P 
P 
P 
TBC1D1/4 P 
Figure 1: IRS/PI3K signaling cascade. 
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 Increases in GLUT4 translocation to the membrane also result from activation of 
the Cbl-CAP insulin signaling pathway.  In the Cbl-CAP pathway, insulin binds to the 
insulin receptor in the cell membrane which then recruits and activates the APS (adaptor 
with pleckstrin homology and Src homology-2 domains) protein (Ahmed et al. 2000; Hu 
and Hubbard 2005).  APS subsequently phosphorylates and activates Cbl (Liu et al. 
2002) which is accompanied by CAP (Ribon et al. 1998a; Ribon et al. 1998b; Lin et al. 
2001).  The activated Cbl-CAP complex ultimately leads to activation of TC10, which 
signals GLUT4 translocation to the cell membrane (Chiang et al. 2001; Chang et al. 
2002).  Some suggest that the Cbl-CAP insulin signaling pathway may be more specific 
to adipose tissue rather than skeletal muscle (JeBailey et al. 2004). 
In addition to glucose metabolism, insulin also modulates fat and protein 
metabolism.  In adipose tissue, insulin, via inhibition of the lipolytic enzyme lipase, 
inhibits lipolysis.  Insulin also stimulates amino acid transport into cells, increases 
translation of mRNA, promotes protein synthesis and storage, and inhibits catabolism of 
proteins (Guyton and Hall 2006). 
 
 
Insulin-independent GLUT4 translocation.  
 
 Insulin does not need to be present in order to signal GLUT4 translocation to the 
membrane to facilitate glucose uptake in the skeletal muscle.  While muscle contraction 
and exercise (Lund et al. 1995; Kennedy et al. 1999), hypoxia (Mu et al. 2001; Wright et 
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al. 2005), and osmotic pressure (Chen et al. 1997) all stimulate glucose transport into 
muscle in the absence of insulin, muscle contraction and exercise has the greatest 
potential to improve glucose uptake in insulin resistant patients.      
AMP-activated protein kinase (AMPK) is a heterotrimeric protein which contains 
a catalytic α subunit and two regulatory subunits (β and γ).  AMPK possesses the ability 
to sense the energy status of a cell and plays a pivotal role in contraction mediated 
glucose transport (Kurth-Kraczek et al. 1999; Mu et al. 2001).  When cellular stores of 
ATP decrease, AMPK is activated via phosphorylation on threonine 172 by kinases such 
as LKB-1 and CAMKKβ (Hurley et al. 2005; Kahn et al. 2005).  AMPK activation can 
also occur by the AMP mimetic 5-aminoimidazole-4-carboxamide-riboside (AICAR) in 
resting muscle to stimulate glucose uptake (Merrill et al. 1997).  The insulin independent 
AMPK signaling and the insulin dependent IRS/PI3K signaling converge at the level of 
TBC1D1/4 activation (Figure 2) (Thong et al. 2007; Taylor et al. 2008).  Phosphorylation 
of AMPK on threonine 172 results in activation of TBC1D1/4 and subsequent GLUT4 
translocation to the membrane.  While both TBC1D1 and TBC1D4 are expressed in 
skeletal muscle, expression of TBC1D1 in adipose tissue is very low (Chavez et al. 2008; 
Taylor et al. 2008).  In skeletal muscle, expression of TBC1D1 may be greater in mixed 
fiber type muscles such as the tibialis anterior compared to the soleus which is made up 
of primarily slow-twitch fibers (Taylor et al. 2008).   
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The energy sensing characteristic of AMPK also allows this protein to regulate 
fatty acid metabolism.  AMPK inhibits the ability of acetyl CoA carboxylase (ACC) to 
form malonyl-CoA (Trumble et al. 1995; Winder et al. 1997).  Decreased levels of 
malonyl-CoA allows for the transfer of long chain fatty acids into the mitochondria via 
carnitine palmitoyltransferase 1 (CPT1) (Ruderman et al. 1999).  Decreasing 
intramuscular fatty acids stores via AMPK activation can improve glucose metabolism by 
increasing skeletal muscle insulin sensitivity (Merrill et al. 1997).  Therefore, activation 
of AMPK may provide a two-fold benefit to improve glucose regulation by directly 
increasing glucose uptake via signaling GLUT4 translocation and by restoring insulin 
sensitivity via decreasing fatty acid stores. 
 
 
Structure and function of GLUT4. 
 
Glucose is a large, hydrophilic molecule which cannot penetrate the lipid bilayer 
of cells.  Instead, glucose is transported across cell membranes via membrane associated 
glucose transporters.  In skeletal muscle and adipose tissue, insulin stimulated glucose 
uptake occurs through GLUT4.  GLUT4 is part of a 13 member GLUT family, whose 
transporters have 12 membrane-spanning helices and an intracellular amino- and 
carboxy- terminus (Joost and Thorens 2001; Scheepers et al. 2004).  Glucose transport 
through GLUT4 occurs via ATP-independent facilitative diffusion (Joost and Thorens 
2001).   
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When serum insulin concentrations are low, most GLUT4 molecules reside in 
intracellular storage vesicles, with 4-5% of GLUT4 proteins present at the plasma 
membrane (Klip et al. 1990).  While the intracellular GLUT4 storage vesicles travel to 
the plasma membrane and undergo exocytosis during this time, the rate of endocytosis of 
GLUT4 proteins is greater than the rate of exocytosis (Satoh et al. 1993; Li et al. 2001).  
In the presence of insulin or activation of AMPK (described earlier), the GLUT4 storage 
vesicles translocate to the plasma membrane to facilitate glucose uptake (Bryant et al. 
2002).  This translocation of GLUT4 storage vesicles occurs via remodeling of the actin 
cytoskeleton (Guilherme et al. 2000).  Further details regarding GLUT4 storage vesicle 
organization, translocation, and fusion with the plasma membrane remain controversial.  
However, GLUT4 likely co-localizes with vesicle-associated membrane protein (VAMP) 
2 in intracellular storage vesicles (Malide et al. 1997).  Exocytosis of GLUT4 storage 
vesicles is likely mediated by VAMP2 and soluble NSF-attachment protein (SNAP) 23 
on the plasma membrane, as assisted by several accessory proteins including munc18c, 
syntaxin4-interacting protein (synip), and tomosyn (Widberg et al. 2003; Hodgkinson et 
al. 2005; Watson and Pessin 2006). 
 
 
Other glucose transport proteins. 
 
 While GLUT4 is the primary regulator of glucose uptake in skeletal muscle and 
adipose tissue, GLUT1 is also present in the plasma membrane of these tissues and 
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facilitates glucose uptake.  GLUT1 is not insulin responsive and remains in the plasma 
membrane to facilitate glucose uptake in the absence of insulin (Bell et al. 1990).  
GLUT1 also facilitates glucose uptake into many tissues in the body, especially 
erythrocytes and the brain.  Neurons obtain glucose via GLUT3 transporters, and the 
liver, kidney, intestine, and pancreatic beta cells obtain glucose via GLUT2 (Joost and 
Thorens 2001).  The kidneys and intestines also obtain glucose via sodium dependent 
glucose transporters (SGLT) (Bell et al. 1990).  These symporters use the concentration 
gradient set up by Na+/K+-ATPase pumps and are, therefore, secondary active 
transporters.  The SGLT facilitate Na+ transport down its concentration gradient, which is 
coupled with glucose transport into the cell (Scheepers et al. 2004).  SGLT are not 
present in skeletal muscle and adipose tissue (Asano et al. 2004).   
 
 
Estrogen receptors.   
 
The first estrogen receptor (ER) was discovered in the rat uterus in 1987 (Koike et 
al. 1987).  Upon discovery of another ER in the rat prostate and ovary in 1996, the former 
ER was re-named ERα and the latter ER named ERβ (Kuiper et al. 1996).  ERα and ERβ 
are products of two distinct genes (Menasce et al. 1993; Enmark et al. 1997).  ERα is 
expressed primarily in the uterus, liver, kidney, and heart and ERβ in the ovary, prostate, 
lung, gastrointestinal tract, bladder, and hematopoietic and central nervous systems 
(Mueller and Korach 2001; Matthews and Gustafsson 2003).  The ERs belong to the 
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nuclear receptor superfamily (Pettersson and Gustafsson 2001) which include the 
classical steroid hormones, orphan receptors, and adopted orphan receptors (reviewed in  
(Glass 2006)).  The ERs belong to the classical steroid hormones which all contain a 
common domain structure.  The C terminus contains a ligand binding domain which is 
responsible for ligand binding, receptor dimerization, and contains a ligand-dependent 
activation function.  The DNA binding domain is located in the center and recognizes 
specific palindromic response elements on target genes.  As the DNA binding domains in 
ERα and ERβ are highly conserved, ERα and ERβ bind estrogen response elements with 
similar affinity and specificity.  However, physiologically, ERα and ERβ act differently 
depending on tissue, receptor level, and presence of ligand, co-activators, and co-
repressors.  The difference in function between ERα and ERβ may stem from a poorly 
conserved ligand-independent activation function located at the N terminus which lacks 
homology among the nuclear receptors (reviewed in (Matthews and Gustafsson 2003)).   
The ERs may initiate cellular function via a genomic or non-genomic mechanism.  
The genomic, or classical, mechanism occurs following ligand binding to the ERs which 
typically reside in the nucleus, although current literature commonly detects the presence 
of ERα in the cytoplasm as well (reviewed in (Deroo and Korach 2006)).  Upon 
activation of the ligand binding domain and receptor dimerization, the ERs bind to 
estrogen response elements on DNA to modulate gene transcription.  The non-genomic 
mechanism of ER action has becoming increasingly important in studying non-
reproductive physiological functions and disease states.  This mechanism of ER action 
occurs following ligand binding to the ERs which reside in the cytoplasm or at the 
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membrane.  The activated ERs then results in cellular responses such as increased levels 
of nitric oxide and calcium or activation of various signaling cascades and kinase activity 
(Kelly and Levin 2001; Nadal et al. 2001; Deroo and Korach 2006).   
 
 
Non-reproductive functions of ERs. 
 
 While the importance of ERs in reproductive functions is well established, the 
ERs are becoming increasingly important in the study and development of cardiovascular 
diseases, brain degeneration, osteoporosis, and glucose metabolism.  Estrogen, via the 
ERs, may protect against cardiovascular diseases by decreasing total cholesterol and LDL 
cholesterol levels in serum (Ohlsson et al. 2000) and also by increasing the vasodilator 
nitric oxide (Haynes et al. 2000).  Activation of the ERs also promotes bone health by 
inhibiting the bone resorption function of nuclear factor-κB (NF-κB) (van den Wijngaard 
et al. 2000; Quaedackers et al. 2001).  The anti-neurodegenerative effects of the ERs 
likely occur through the inhibition of apoptosis (Dubal et al. 1999; Maggi et al. 2000).  
Many of these non-reproductive functions of the ERs occur through the recently 
discovered non-genomic mechanisms previously mentioned.  The ERs also play a role in 
glucose metabolism, with ERα and ERβ knockout (KO) mice providing much of the 
initial understanding of ER regulation of glucose control. 
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ER KO mice and glucose metabolism. 
 
 Glucose regulation in the body mostly occurs in the skeletal muscle, adipose 
tissue, and liver.  ER KO mice suggest that the ERs may play a role in glucose regulation 
in all of these tissues, with the primary mediator being ERα.  With respect to the liver, 
ERα KO mice show hepatic insulin resistance during the euglycemic-hyperinsulinemic 
clamp test.  While hepatic glucose production decreases in wild-type (WT) mice, insulin 
is not able to decrease hepatic glucose production in ERα KO mice (Bryzgalova et al. 
2006).   
With respect to the adipose tissue, ERα KO mice have increased body weight and 
white adipose tissue weight compared to WT mice.  ERα KO mice also have increased 
adipocyte size and number, although food intake does not differ (Heine et al. 2000).  
Similarly, aromatase KO mice, in which androgens cannot be converted to E2, have 
increased body weight (Takeda et al. 2003) and adipose tissue weight (Fisher et al. 1998) 
compared to WT mice.  In contrast, ERβ KO mice do not have increased adipose tissue 
weight or percent body fat compared to WT mice (Ohlsson et al. 2000).  Therefore, 
E2/ERα signaling appears to be an important regulator of body weight and adipocyte 
regulation.   
In addition, ERα KO mice display a decrease in whole body glucose tolerance and 
insulin sensitivity and have decreased glucose uptake in the skeletal muscle (Heine et al. 
2000; Bryzgalova et al. 2006; Ribas et al. 2009).  ERα KO mice also have increased 
fasting glucose and insulin levels, which are not present in ERβ KO mice (Bryzgalova et 
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al. 2006).  Aromatase KO mice also display a decrease in whole body glucose tolerance 
and increased insulin resistance, both of which can be ameliorated with E2 replacement 
(Takeda et al. 2003).  In addition, a case study of a human male lacking a functional ERα 
has impaired glucose tolerance and hyperinsulinemia (Smith et al. 1994).  Likewise, 
humans that have aromatase deficiency are also hyperinsulinemic (Morishima et al. 
1995).  These data again suggest the importance of E2/ERα signaling in whole body and 
skeletal muscle glucose regulation.  As skeletal muscle is responsible for over 75% of the 
glucose regulation that occurs in the body (Bjornholm and Zierath 2005), understanding 
how E2/ERα may be involved in skeletal muscle glucose metabolism could have a great 
impact on managing glucose regulation in the body.   
 
 
Mechanisms of ER mediated glucose metabolism. 
 
Recently, investigators utilized cell culture to examine the mechanism by which 
estrogen may play a role in glucose metabolism.  Studies show that estrogen treatment in 
adipocytes increases insulin-stimulated glucose uptake and activation of the insulin 
signaling pathway more than insulin alone (Muraki et al. 2006; Nagira et al. 2006).  
Furthermore, Muraki et al. found that the beneficial effects of estrogen were abolished 
when adipocytes were co-treated with methylpiperidinopyrazole (MPP), a specific ERα 
inhibitor.  The beneficial effects were restored with treatment of propylpyrazoletriol 
(PPT), a specific ERα activator (Muraki et al. 2006).  These studies suggest that 
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activation of ERα can potentiate the insulin signaling pathway and glucose uptake in 
cultured adipocytes.   
In skeletal muscle, E2 may act on the insulin signaling pathway in a similar 
manner.  Acute E2 incubations (5 and 10 minutes) with skeletal muscle in vitro can 
increase activation of the insulin signaling pathway, including phosphorylation of Akt 
and its downstream targets, AS160 and TBC1D1 (Rogers et al. 2009).  Furthermore, 
long-term E2 treatment in vivo can improve whole body and skeletal muscle glucose 
metabolism in animals fed a high-fat diet (Riant et al. 2009).  Therefore, activation of the 
estrogen receptors has the potential to positively modulate skeletal muscle glucose 
metabolism. 
Additional studies suggest a second mechanism in which E2 may play a role in 
glucose metabolism via regulation of GLUT4.  GLUT4 is absolutely critical for glucose 
uptake in skeletal muscle.  Regardless of the insulin signaling pathway’s ability to 
function, low levels of GLUT4 can limit the rate of glucose uptake into the cell.  NF-κB 
is a transcription factor that is activated by stimuli such as cellular stress, cytokines, and 
inflammation.  The promoter region of GLUT4 contains a NF-κB binding site (Long and 
Pekala 1996b), and NF-κB represses GLUT4 transcription (Ruan et al. 2002).  In a basal 
state, NF-κB is bound by the inhibitor of kappa B α (IκBα) in the cytosol and remains 
inactive.  Upon activation of the stress kinase proteins, IκBα is phosphorylated, which 
signals its degradation by the proteosome.  The free NF-κB is then activated and 
translocates to the nucleus where it functions as a transcription factor.  Tumor necrosis 
factor α (TNF-α) is a cytokine that activates the NF-κB pathway and is highly expressed 
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in obese humans (Saghizadeh et al. 1996; Uysal et al. 1998).  In addition, obese humans 
with T2DM have increased skeletal muscle NF-κB activation (Sriwijitkamol et al. 2006).  
Previous studies have also shown that rats on an obesity-promoting high-fat diet have 
decreased skeletal muscle GLUT4 protein (Kahn 1994; Han et al. 1995; Sevilla et al. 
1997).  Overall, these studies suggest that obesity increases the amount of TNF-α and 
leads to NF-κB activation, which is followed by a decrease in GLUT4 protein levels.   
Estrogen’s involvement in GLUT4 regulation comes in to play as new evidence 
points to NF-κB being regulated by ERα.  While the ERs traditionally modulate gene 
expression by binding directly to DNA, studies also show that ERα modulates gene 
expression without binding directly to DNA, but by binding other transcription factors 
(Galien and Garcia 1997; Paech et al. 1997; Qin et al. 1999).  Cell culture studies have 
shown that activated ERα can directly bind to NF-κB and decrease NF-κB–DNA binding 
(Stein and Yang 1995; Galien and Garcia 1997; Ray et al. 1997; Paimela et al. 2007).  In 
the case of GLUT4, NF-κB is a negative transcription factor.  With low levels of 
activated ERα, NF-κB may remain unchecked and decrease GLUT4 levels.  In fact, 
females with polycyctic ovarian syndrome who have high androgen and low estrogen 
levels (and, therefore, have low ERα activation) have 35% less GLUT4 protein compared 
to control females (Rosenbaum et al. 1993).  In addition, ERα KO mice show a decrease 
in GLUT4 mRNA levels (Barros et al. 2006b).  Therefore, increased NF-κB activation 
via a high-fat diet and obesity combined with low ERα activation could decrease GLUT4 
transcription, leading to a subsequent decrease in glucose uptake and insulin resistance.  
37 
 
This physiological condition (obesity and low E2 levels) is present in most 
postmenopausal women, putting these women at a particular risk for insulin resistance. 
 
 
GLUT4 transcriptional regulation. 
 
 GLUT4 protein levels change due to alterations in metabolism, hormones, and 
nutrition, and several transcription factors have been implicated in the regulation of 
GLUT4.  GLUT4 mRNA and protein is decreased in the adipose tissue of obese humans 
and humans with T2D (Garvey et al. 1991; Pedersen et al. 1992; Shepherd and Kahn 
1999).  In skeletal muscle, GLUT4 is only decreased in morbidly obese humans 
(Shepherd and Kahn 1999).  In animal models of obesity and T2D, discrepancies exist as 
to whether GLUT4 is decreased in the skeletal muscle and adipose tissue.  In the db/db 
mouse model of obesity and T2D, in which the leptin receptor activity is deficient due to 
a point mutation, GLUT4 levels remain unchanged in both the adipose tissue and skeletal 
muscle (Friedman et al. 1992).   In contrast, Zucker diabetic fatty rats display decreased 
GLUT4 in both the skeletal muscle and adipose tissue (Marette et al. 1993).  However, 
non-genetic animal models of obesity and T2D may better compare to human studies of 
GLUT4 regulation.   
The high-fat feeding model assesses changes in adiposity, glucose metabolism, 
fatty acid regulation, and numerous other cellular mechanisms related to the pathogenesis 
and development of insulin resistance, glucose intolerance, and T2D.  Previous studies 
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show a decrease in GLUT4 protein in adipose tissue in rodents fed a high-fat diet 
(Leturque et al. 1991; Pedersen et al. 1991; Kahn 1994; Ikemoto et al. 1995).  In skeletal 
muscle, a high-fat diet may (Kahn and Pedersen 1993; Han et al. 1995; Sevilla et al. 
1997; Tremblay et al. 2001) or may not (Kusunoki et al. 1993; Rosholt et al. 1994; 
Zierath et al. 1997) decrease GLUT4 protein levels.  Whether or not a high-fat diet 
decreases skeletal muscle GLUT4 may depend on the fatty acid composition of the diet.  
Diets high in arachidonic, stearic, and oleic acids may contribute to decreased GLUT4 
expression (Tebbey et al. 1994; Long and Pekala 1996b).  These fatty acids are omega-6 
(arachidonic), saturated (stearic), and omega-9 (oleic) fatty acids that are very common in 
the western diet, as opposed to omega-3 fatty acids such α-linolenic acid (ALA), 
eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) that are less common in 
the western diet.  Although the mechanism by which a high-fat diet and/or obesity may 
contribute to decreased GLUT4 expression remains uncertain, tumor necrosis factor-α 
(TNF-α), nuclear factor-κB (NF-κB), and CCAAT/enhancer binding protein-α (C/EBP-α) 
may all work to suppress GLUT4 levels.  The promoter region of GLUT4 contains a NF-
κB binding site (Long and Pekala 1996a), and NF-κB represses GLUT4 transcription 
(Ruan et al. 2002).  Fatty acids may induce activation of NF-κB to decrease GLUT4 
(Jove et al. 2006), or TNF-α may activate NF-κB.  TNF-α is a cytokine that activates the 
NF-κB pathway and is highly expressed in obese humans (Saghizadeh et al. 1996; Uysal 
et al. 1998).  TNF-α can also repress GLUT4 gene expression through C/EBP-α in 
adipocytes (Liu and Matsumura 2006).   
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Insulin status can also alter GLUT4 protein levels.  A decrease in insulin as 
induced by streptozotocin (Berger et al. 1989; Garvey et al. 1989; Sivitz et al. 1989; Kahn 
et al. 1991; Slieker et al. 1992; Napoli et al. 1995) or fasting (Berger et al. 1989; Sivitz et 
al. 1989; Charron and Kahn 1990) in animal models decreases GLUT4 in the adipose 
tissue, and re-feeding after a fast rapidly increases GLUT4 above pre-fasting levels 
(Berger et al. 1989; Sivitz et al. 1989; Charron and Kahn 1990).  In skeletal muscle, 
numerous studies also support a streptozotocin-induced decrease in GLUT4 mRNA and 
protein levels (Bourey et al. 1990; Garvey et al. 1991; Kahn et al. 1991; Napoli et al. 
1995; Munoz et al. 1996).  However, this may only occur in primarily slow-twitch 
muscles, but not primarily fast-twitch muscles (Neufer et al. 1993).  In contrast to adipose 
tissue, a three day fast increases skeletal muscle GLUT4 mRNA expression, although 
discrepancies exist as to which fiber type this occurs in.  Fasting has been shown to 
increase GLUT4 mRNA in skeletal muscle made up of mixed and primarily slow-twitch 
fibers (Charron and Kahn 1990), although another report shows no change in primarily 
slow-twitch muscles, but an increase in primarily fast-twitch muscles (Neufer et al. 
1993).  Numerous transcription factors are activated or repressed upon decreased insulin 
levels and may contribute to these discrepancies.  While the exact mechanisms of insulin-
mediated GLUT4 transcriptional control remain unknown, sterol regulatory element 
binding protein-1 (SREBP-1) (Im et al. 2006), peroxisome proliferator activated receptor-
α (PPAR-α) (Yechoor et al. 2002; Patti et al. 2003), olf-1/early B cell factor-1 (O/E-1) 
(Dowell and Cooke 2002), and nuclear factor-1 (NF-1) (Cooke and Lane 1999), and 
C/EBP-α (Kaestner et al. 1990) may all play a role. 
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In skeletal muscle, exercise-induced contraction of muscle fibers (Winder et al. 
2006) and exercise training (Ploug et al. 1990; Wake et al. 1991) can also increase 
GLUT4 levels.  Central to this regulation is myocyte enhancer factor 2 (MEF2).  MEF2 is 
regulated by AMPK, a protein activated by muscle contraction (Knight et al. 2003; Ojuka 
2004).  AMPK also activates PPAR-γ coactivator 1 (PGC-1) (Ojuka 2004) and muscle 
GLUT4 enhancer factor (mGEF) (Knight et al. 2003).  Together, MEF2, PGC-1, and 
mGEF work to increase GLUT4 as simulated by muscle contraction (Michael et al. 2001; 
Knight et al. 2003; Holmes et al. 2005).  Kruppel-like Factor (KLF) 15 and myoD also 
work synergistically with MEF2 to upregulate GLUT4 gene expression (Czubryt et al. 
2003).   
 
 
Transgenic models used to study GLUT4. 
 
 Knocking out the activity of a specific gene can provide general information on 
the whole body impact of that gene.  Surprisingly, GLUT4 knockout (KO) mice maintain 
normal plasma glucose levels, even following a GTT (Katz et al. 1995).  However, these 
mice display hyperinsulinemia and insulin resistance in the fed state.  As predicted, 
insulin-stimulated glucose transport into the skeletal muscle is abolished (Stenbit et al. 
1996).  Although GLUT4 KO mice do not display severe impairments of glucose 
metabolism, the importance of GLUT4 expression particularly presents itself in models 
of T2D.  While a high-fat diet results in glucose intolerance in mice, a two-fold increase 
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in GLUT4 expression, via transgenic overexpression, protects against the high-fat diet-
induced glucose intolerance (Ikemoto et al. 1995). 
To better understand the role of GLUT4 in insulin-responsive tissues, mouse 
models have been developed which alter GLUT4 levels specifically in skeletal muscle 
and adipose tissue.  Abel et al. developed an adipose-specific GLUT4 KO (Abel et al. 
2001).  These mice exhibit whole body insulin resistance and glucose intolerance, albeit 
no increase in body weight.  GLUT4 expression is reduced by 70% in the adipose tissue, 
but unaltered in the skeletal muscle.  Basal glucose transport in the adipose tissue is 
decreased by 40%, and insulin-stimulated glucose transport is decreased by 72%, 
accounting for much of the whole body insulin resistance and glucose intolerance.  
However, although no changes in GLUT4 levels occur in the skeletal muscle, these mice 
also display decreased glucose transport into the skeletal muscle.   These authors suggest 
that cross-talk between adipose tissue and skeletal muscle may mediate this change due 
to secreted factors from the adipose tissue such as retinol binding protein 4.  
Overexpression of GLUT4 specifically in the adipose tissue increases basal and insulin-
stimulated glucose transport into the adipose tissue (Shepherd et al. 1993), and these 
transgenic mice are partially protected against streptozotocin-induced diabetes (Tozzo et 
al. 1997).  Therefore, GLUT4 levels in the adipose tissue play an important role in whole 
body glucose regulation.   
 Zisman et al. developed a skeletal muscle-specific GLUT4 KO (Zisman et al. 
2000).  These mice develop insulin resistance and glucose intolerance by eight weeks of 
age, and GLUT4 expression in the skeletal muscle is reduced by 95%.  Non-insulin 
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stimulated glucose transport is decreased by 80% in the skeletal muscle, and insulin 
stimulation does not increase glucose transport.  Secondary insulin resistance also 
develops in the adipose tissue, which is likely a result of glucose toxicity (Kim et al. 
2001).  Therefore, the presence of the insulin-responsive GLUT4 protein in skeletal 
muscle is important to ward off T2D and protect the body from glucose toxicity.   
 
 
Research Goals. 
 
 Research focusing on the function of E2 in skeletal muscle and adipose tissue 
glucose metabolism is gaining attention, and much more information has become 
available in the past few years.  However, many gaps still exist in the literature.  We 
assessed the outcome of a physiological model of insulin resistance combined with OVX 
on skeletal muscle and adipose tissue ER expression and glucose metabolism.  
Furthermore, we sought to determine the ability of activated ERα to modulate glucose 
uptake, insulin signaling, and GLUT4 in the skeletal muscle.  Finally, as adipogenesis 
remains an important risk factor for T2D, we examined the extent to which activation of 
ERα may regulate fat storage and proteins involved in lipogenesis and lypolysis.   
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ABSTRACT 
Estrogen receptors (ERs) are expressed in adipose tissue and skeletal muscle, with 
potential implications for glucose metabolism and insulin signaling. Previous studies 
examining the role of ERs in glucose metabolism have primarily used knockout mouse 
models of ERα and ERβ and it is unknown whether ER expression is altered in response 
to an obesity-inducing high-fat diet (HFD). The purpose of the current study was to 
determine whether modulation of glucose metabolism in response to a HFD in intact and 
ovariectomized (OVX) female rats is associated with alterations in ER expression. Our 
results demonstrate that a 6 week HFD (60% calories from fat) in female rats induces 
whole body glucose intolerance with tissue specific effects isolated to the adipose tissue, 
and no observed differences in insulin-stimulated glucose uptake, GLUT4, or ERα 
protein expression levels in skeletal muscle. In chow-fed rats, OVX resulted in decreased 
ERα with a trend towards decreased GLUT4 expression in adipose tissue. Sham and 
OVX rats fed a HFD demonstrated a decrease in ERα and GLUT4 in adipose tissue. The 
HFD also increased activation of stress kinases (c-jun NH2-terminal kinase and inhibitor 
of kappa B kinase β) in the sham rats and decreased expression of the protective heat 
shock protein 72 (HSP72) in both sham and OVX rats. Our findings suggest that 
decreased glucose metabolism and increased inflammation in adipose tissue with a HFD 
in female rats could stem from a significant decrease in ERα expression.  
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INTRODUCTION 
Type 2 diabetes, one of the main causes of mortality and morbidity worldwide 
(Saltiel and Kahn 2001), is characterized by insulin resistance, glucose intolerance, and 
inflammation, and is closely associated with obesity. Clinical evidence suggests 
postmenopausal women have an increased risk of glucose intolerance and weight gain, 
and that this is accompanied by increased inflammation and decreased insulin sensitivity 
(Pfeilschifter et al. 2002; Sites et al. 2002; Carr 2003). Estrogen replacement therapy in 
postmenopausal women ameliorates the increased risk of type 2 diabetes (Andersson et 
al. 1997; Kanaya et al. 2003; Margolis et al. 2004), even in the presence of increased 
abdominal fat (Gower et al. 2006). While this beneficial effect of estrogen is evident, the 
molecular mechanisms of estrogen and its active metabolite, 17β-estradiol (E2), in 
metabolic tissue remain unknown.  
Estrogen exerts its effects through two nuclear receptors, estrogen receptor (ER) α 
and ERβ (Dahlman-Wright et al. 2006). ERα and ERβ are expressed in adipose tissue 
and skeletal muscle, with potential implications for glucose metabolism and insulin 
signaling. Previous studies demonstrate that ERα knockout mice are obese, insulin 
resistant, and exhibit glucose intolerance (Heine et al. 2000; Bryzgalova et al. 2006). A 
recent study by Ribas et al. (Ribas et al. 2009) further showed that ERα expression is 
critical for the maintenance of whole body insulin action and protection against tissue 
inflammation in response to high-fat feeding. These investigators suggest that ERα could 
play an important role in modulating inflammatory stress kinase proteins such as c-Jun 
NH2-terminal kinase (JNK) (Ribas et al. 2009), known to interfere with insulin signaling 
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(Chung et al. 2008; Gupte et al. 2009a; Gupte et al. 2009b; Ribas et al. 2009). Despite 
this important new information, the role of ERs in the pathogenesis of insulin resistance 
and glucose intolerance is not clear. Previous studies examining the role of ERs in 
glucose metabolism have primarily used knockout mouse models of ERα and ERβ and it 
is unknown whether ER expression is altered in response to an obesity-inducing high-fat 
diet (HFD).  As a result, the impact of a HFD on ER expression in adipose tissue and 
skeletal muscle, and thus the role of ERs in mediating the metabolic actions of estrogen, 
remains a fundamental question. Therefore, the purpose of the current study was to 
determine whether modulation of glucose metabolism in response to a HFD in intact and 
ovariectomized female rats is associated with alterations in ER expression.  
 
MATERIALS AND METHODS 
Materials.  GLUT4 antibody (ab654) was purchased from Abcam (Cambridge, 
MA), ERα (MC-20) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA), 
ERβ (#PA1-310B) was purchased from Affinity BioReagents (Rockford, IL), and HSP72 
was purchased from Stressgen (Victoria, BC, Canada). Phospho-SAPK/JNK 
(T183/Y185), total SAPK/JNK, and IκBα were purchased from Cell Signaling (Beverly, 
MA). Goat anti-mouse HRP-conjugated secondary antibody was obtained from Bio-Rad 
(Hercules, CA) and donkey anti-rabbit HRP-conjugated secondary antibody was 
purchased from Jackson (West Grove, PA). Enhanced chemiluminescence reagents were 
purchased from Fisher Scientific (Pittsburg, PA). [14C]mannitol and 2-deoxy-[1,2-
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3H]glucose were purchased from American Radiolabeled Chemicals (St. Louis, MO). All 
other reagents were obtained from Sigma. 
Experimental animals and treatment.  Female Sprague Dawley rats (5 months 
old) were purchased from Charles River Laboratories (Wilmington, MA) and singly 
housed in a temperature-controlled (22 ± 2°C) room with 12-h light and dark cycles. 
Chow rats were fed ad libitum on a soy protein free diet (Harlan Teklad 2020X, Madison, 
WI, 10% calories from fat), whereas HF rats received a modified Kraegen diet (Storlien 
et al. 1986) of 60% calories from fat for 6 wk as previously used (Gupte et al. 2009a) 
which contains the following: 254 g/kg casein, 85 g/kg sucrose, 169 g/kg cornstarch, 11.7 
g/kg vitamin mix, 1.3 g/kg choline chloride, 67 g/kg mineral mix, 51 g/kg bran, 3 g/kg 
methionine, 19 g/kg gelatin, 121 g/kg corn oil, 218 g/kg lard. A pre-set amount of food 
(in excess of what was needed) was administered to each animal. The remaining food 
was weighed two to three days later, prior to giving a new batch of food. At the start of 
the diet, animals underwent ovariectomy (OVX) or sham surgery under 
ketamine/atropine/xylazine anesthesia (60 mg/kg body wt ketamine, 0.4 mg/kg body wt 
atropine, 8 mg/kg body wt xylazine). Bilateral flank incisions were made under aseptic 
conditions. The ovaries were identified and either bilaterally removed via cauterization 
(OVX) or left intact (sham).  Wounds were closed using sutures and wound clips. The 
following four groups were assessed (n= 5-6 rats/group): 1) Chow Sham; 2) Chow OVX; 
3) HF Sham; and 4) HF OVX. All protocols were approved by the Animal Care and Use 
Committee of the University of Kansas Medical Center. 
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Intraperitoneal glucose tolerance test.  An intraperitoneal glucose tolerance test 
(IPGTT) was performed during week 6 of the diet regimen. Overnight-fasted rats were 
anesthetized with an intraperitoneal injection of pentobarbital sodium (2.5 mg/100 g body 
wt) and given a glucose load of 2 g/kg body wt in 0.9% saline. Tail blood samples were 
measured with a glucometer (Accu-Check) at time points 0, 15, 45, 60, 90, and 120 
minutes after glucose injection. Serum insulin was measured via an ELISA according to 
the manufacturer’s instructions (Alpco Diagnostics, 80-INSRT-E01; Salem, NH). 
Tissue dissection.  During week 7, overnight-fasted animals were anesthetized 
under ketamine/atropine/xylazine anesthesia (60 mg/kg body wt ketamine, 0.4 mg/kg 
body wt atropine, 8 mg/kg body wt xylazine). One soleus and one extensor digitorum 
longus (EDL) muscle was dissected from each animal, each split longitudinally into 
strips, and assessed for glucose transport. The remaining soleus and EDL muscle from 
each animal was frozen in liquid nitrogen for Western blot analysis. Gonadal fat was 
removed from the ovaries and uterine horns, weighed, and then frozen in liquid nitrogen. 
The uterus was also removed and weighed.   
Measurement of glucose transport activity.  Glucose transport was measured in 
soleus and EDL muscle strips as previously described (Gupte et al. 2009b). Muscles 
strips recovered for 60 min in flasks containing 2 ml of Krebs-Henseleit bicarbonate 
buffer (KHB) with 8 mM glucose, 32 mM mannitol, and a gas phase of 95% O2-5% CO2. 
The flasks were placed in a shaking incubator maintained at 35°C. Following recovery, 
the muscles were rinsed for 30 min at 29°C in 2 ml of oxygenated KHB containing 40 
mM mannitol, with or without insulin (2 mU/ml). After the rinse step, muscles were 
49 
 
incubated for 20 min at 29°C in flasks containing 2 ml KHB with 4 mM 2-[1,2-
3H]deoxyglucose (2-DG) (1.5 μCi/ml) and 36 mM [14C]mannitol (0.2 μCi/ml), with or 
without insulin (2 mU/ml), with a gas phase of 95% O2-5% CO2 in a shaking incubator. 
The muscles were then blotted dry, clamp frozen in liquid nitrogen, and processed as 
described previously (Young et al. 1986; Geiger et al. 2006) for determination of 
intracellular 2-DG accumulation (3H dpm) and extracellular space (14C dpm) on a 
scintillation counter. 
Serum estradiol measurement. Blood samples were collected at time of sacrifice 
and allowed to clot at room temperature for 30 minutes. Samples were spun at 17,500 x g 
for 20 minutes at 4°C. Serum estradiol levels were measured by Estradiol E2 Coat-a-
Count Assay (Siemens Diagnostics, TKE21). 
Western blotting.  Muscles clamp frozen in liquid nitrogen were homogenized in a 
12:1 (volume-to-weight) ratio of ice-cold buffer from Biosource (Invitrogen, Camarillo, 
CA) containing 10 mM Tris·HCl (pH 7.4); 100 mM NaCl; 1 mM each of EDTA, EGTA, 
NaF, and phenylmethylsulfonyl fluoride; 2 mM Na3VO4; 20 mM Na4P2O7; 1% Triton 
X-100; 10% glycerol; 0.1% SDS; 0.5% deoxycholate; and 250μl/5ml protease inhibitor 
cocktail. Homogenized samples were rotated for 30 minutes at 4°C and then centrifuged 
for 20 minutes at 3,000 rpm at 4°C. The protein concentration of the supernatant was 
determined by the Bradford method (Bio-Rad). Samples were prepared in 5X Laemmli 
buffer containing 100 mM dithiothreitol and boiled in a water bath for 5 minutes. 
Samples analyzed for GLUT4 protein were not boiled. Protein (30–75 μg) was separated 
on a SDS-PAGE (8.75–10%) gel followed by a wet transfer to a nitrocellulose membrane 
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for 60–90 minutes (200 mA). Total protein was visualized by Ponceau staining, and blots 
were normalized to the 45kDa band as previously described (Gupte et al. 2008). As the 
GLUT4 antibody only works with non-denatured protein, we chose to normalize all 
protein measurements to Ponceau staining, which does not require denaturing. 
Membranes were blocked for 1 hour at room temperature in 5% nonfat dry milk in Tris-
buffered saline with 0.1% Tween 20 (TBST) and then incubated overnight with the 
appropriate primary antibodies. Antibodies were diluted in 1% nonfat dry milk in TBST 
or in 1% bovine serum albumin in TBST. Blots were incubated in a HRP-conjugated 
secondary antibody in 1% nonfat dry milk in TBST for 1 hour at room temperature and 
visualized by ECL. Bands were quantified using Image J densitometry. To serve as a 
positive control for ERα, uterine tissue was initially used to detect and quantify 
expression of the full length 66 kDa protein. 
Statistical analysis.  Results are presented as means + SE. Statistical significance 
was set at P < 0.05 and determined by One-way or Two-way ANOVA and Student-
Newman-Keuls post hoc test.   
 
RESULTS 
Effects of diet and OVX on food intake and body composition.  Uterine weight 
is a commonly used bioassay to assess in vivo estrogen status. In the current study, OVX 
rats had significantly lower uterine weight compared to sham (0.415 + 0.016 mg/g body 
weight vs. 1.618 + 0.108 mg/g body weight; P < 0.001), confirming negligible estrogen 
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influence in OVX rats as a result of surgically removing the ovaries. To confirm the in 
vivo estrogen status, serum E2 levels were also measured. OVX significantly decreased 
serum E2 levels compared to sham treated animals (7.6 + 0.9 pg/mL vs. 11.9 + 1.8 
pg/mL; P<0.05) which is consistent with previous reports in the literature (Haim et al. 
2003; Imaoka et al. 2009). The 6 week HFD did not significantly alter uterine weight or 
serum E2 levels in either OVX or sham treated animals, consistent with previously 
reported data (Bryzgalova et al. 2008; Akamine et al. 2010). Over the course of the 6 
week diet regimen, female rats that underwent OVX demonstrated greater average daily 
food intake and increased body weight compared with sham rats, with no significant 
difference in food intake or weight gain as a result of the HFD in sham rats (Figures 3A 
and 3B). OVX animals fed a HFD demonstrated greater food intake and weight gain 
compared to all other groups. Both groups of HFD animals gained most of their weight in 
first 2-3 weeks of high-fat feeding. However, the body weight of the animals that 
underwent OVX and were fed a HFD increased at a greater rate during this period. After 
week 3, the OVX animals fed the HFD continued to gradually increase their body weight 
and the sham animals fed the HFD remained fairly constant. Assessment of fat mass, as 
measured by gonadal fat pad weight, revealed a different pattern from that observed for 
food intake and body weight. In spite of increased food intake and body weight as a result 
of OVX, no increase in gonadal fat was observed in this group (Figure 3C). The HFD 
resulted in a significant increase in gonadal fat pad weight in both sham- and OVX-
treated rats.   
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Figure 3. The combination of High Fat Diet (HFD) and ovariectomy (OVX) increases 
food intake, body weight, and gonadal fat weight.  Average daily food intake was 
measured over the course of a 6 week chow or HFD (A), and body weight was measured 
weekly (B). At the end of the 6 week study, gonadal fat weight (C) was measured. Values 
are means + SE for 5-6 rats per group.  *p<0.05 vs. chow sham; +p<0.05 vs. HF sham; 
#p<0.05 vs. chow OVX.   
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Effects of diet and OVX on glucose tolerance.  Fasting glucose and insulin levels did 
not differ across experimental groups at the end of the 6 week diet (Figures 4A and 4B, 
respectively). An intraperitoneal glucose tolerance test (IPGTT) was performed to assess 
whole body glucose clearance in response to a glucose challenge. The HFD resulted in a 
decrease in whole body glucose tolerance, as demonstrated by the inability of HFD rats to 
effectively clear glucose from their blood by the end of the 2 h test, compared to rats fed 
a chow diet (Figure 4C). While OVX rats fed a HFD had slightly lower glucose values 
throughout the test, these values were not significantly different from sham animals fed a 
HFD. Similarly, OVX did not significantly alter glucose clearance in chow-fed rats 
compared to sham controls. Serum insulin levels during the IPGTT did not differ among 
the groups (data not shown). 
Effects of diet and OVX on insulin-stimulated skeletal muscle glucose uptake.  
To investigate the effects of diet and OVX on skeletal muscle glucose uptake, we 
performed 2-DG uptake assays on the predominately slow-twitch soleus or the 
predominately fast-twitch EDL muscles. Insulin-stimulated glucose uptake increased 
above basal in all groups examined (Figures 5A and 5B, respectively). However, no 
differences in basal- or insulin-stimulated skeletal muscle glucose uptake were observed 
across treatment groups in either the soleus or EDL muscles.  
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A 
B 
C 
Figure 4. A six week HFD decreases glucose tolerance in female rats.  At the end of the 6 
week diet, rats were fasted overnight and fasting blood glucose (A) and fasting serum insulin 
(B) were measured. An intraperitoneal glucose tolerance test (IPGTT) was then performed (C). 
Rats were injected with a glucose load of 2 g/kg body wt i.p. Blood glucose was measured at 
time 0, 15, 30, 60, 90, and 120 min after injection using a glucometer. Values are means + SE 
for 5-6 rats per group. Serum insulin values are means + SE for 2-6 rats per group.  *P<0.05 vs. 
chow sham. 
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A 
B 
Figure 5. Insulin-stimulated skeletal muscle glucose transport was not altered by a 
HFD or OVX.  Insulin-stimulated glucose transport was measured in soleus (A) and EDL 
(B) muscles. Muscles were incubated in the absence of insulin (open bars) or in the 
presence of insulin (2 mU/ml, solid bars), along with 2-[1,2-3H]deoxyglucose and 
[14C]mannitol. Values are means + SE for 5-6 rats per group. *P<0.05 insulin vs. basal. 
 
Chow Sham Chow OVX HF Sham HF OVX
2-
D
eo
xy
 G
lu
co
se
 U
pt
ak
e 
(µ
m
ol
/m
L/
20
m
in
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
*
*
*
*
Chow Sham Chow OVX HF Sham HF OVX
2-
D
eo
xy
 G
lu
co
se
 U
pt
ak
e
(µ
m
ol
/m
L/
20
m
in
)
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
*
* * *
56 
 
Effects of diet and OVX on ERα, ERβ, and GLUT4 protein levels. The effects of 
high-fat feeding on ER protein expression in metabolic tissue has not been previously 
examined in non-transgenic animal models. ERα and ERβ are both prevalent in skeletal 
muscle and adipose tissue, with ERα expression shown to be more highly expressed than 
ERβ in insulin-sensitive tissue (Ribas et al. 2009). Neither OVX nor the HFD had an 
effect on ERα expression in the soleus or EDL muscles (Figures 6A and 6B). However, 
ERα expression was significantly decreased in adipose tissue in response to OVX and the 
HFD (Figure 6C). In OVX rats fed a HFD, the decrease in ERα was not greater than with 
either intervention alone.  In contrast with ERα expression, there was an effect of OVX 
and diet on ERβ expression in skeletal muscle, but these effects were isolated to the 
soleus muscle. In this muscle, OVX and a HFD resulted in significant decreases in ERβ 
expression compared to sham controls (Figure 6D). The combination of a HFD with 
OVX did not result in a greater decrease in ERβ expression in soleus muscle and no 
changes with OVX or diet were observed in the EDL muscle (Figure 6E). In the adipose 
tissue, ERβ expression was unchanged by OVX or a HFD (Figure 6F).  
The effect of a HFD on GLUT4 protein expression is equivocal with some studies 
demonstrating a decrease or no change in GLUT4 protein expression as a result of high-
fat feeding (Kahn and Pedersen 1993; Kusunoki et al. 1993; Rosholt et al. 1994; Han et 
al. 1995; Sevilla et al. 1997; Zierath et al. 1997; Tremblay et al. 2001). In female rats 
subject to OVX or sham surgery, a 6 week HFD had no effect on GLUT4 protein 
expression in either the soleus or EDL muscle (Figures 7A and 7B). However, the HFD 
dramatically reduced GLUT4 protein expression in adipose tissue in both sham- and 
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B A 
Figure 6.  
 
OVX- treated rats (65% and 52%, respectively, Figure 7C). OVX in chow-fed rats 
resulted in lower GLUT4 levels in adipose tissue compared to sham-treated chow rats, 
although these differences were not statistically significant (P = 0.07).  
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Figure 6. HFD and OVX decrease ERα in adipose tissue and ERβ in soleus muscle.  ERα 
(A-C) and ERβ (D-F) protein levels were measured in the soleus (A, D) and EDL (B, E) 
muscles and adipose tissue (C, F) by Western blot analysis. Protein levels were normalized to 
total protein measured by Ponceau staining. Values are means + SE for 5-6 samples per group.  
*P<0.05 vs. chow sham. 
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Figure 7. HFD and OVX decrease GLUT4 protein levels in adipose tissue.  Protein 
levels were measured in soleus muscle (A), EDL muscle (B), and adipose tissue (C) by 
Western blot analysis. Protein levels were normalized to total protein measured by Ponceau 
staining. Values are means + SE for 5-6 muscles per group.  *P<0.05 vs. chow sham. 
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Effects of diet and OVX on stress kinases and HSP72 protein levels.  
Activation of the stress kinases c-Jun NH2-terminal kinase (JNK) and inhibitor of kappa 
B kinase β (IKKβ) were assessed via Western blot analysis. JNK activation was assessed 
by measuring changes in JNK protein phosphorylation and IKKβ by protein levels of 
IκBα, the downstream protein targeted for degradation by IKKβ. JNK phosphorylation 
was increased as a result of the HFD in adipose tissue (Figure 8A), but no change in JNK 
phosphorylation occurred in either soleus or EDL muscle in response to diet (data not 
shown). JNK phosphorylation with OVX treatment alone or in combination with a HFD 
was not different than chow-fed sham animals in adipose tissue or skeletal muscle. 
Activation of IKKβ was also increased with the HFD in adipose tissue, as indicated by 
decreased expression of IκBα (Figure 8B). No changes in adipose tissue IκBα protein 
expression occurred with OVX in either chow or high fat-fed rats. In addition, no changes 
were observed in IκBα expression in either the soleus or EDL muscle as a result of diet or 
OVX (data not shown).  6 weeks of a HFD dramatically decreased protein levels of heat 
shock protein 72 (HSP72) in the adipose tissue of both sham-treated and OVX rats 
(Figure 8C).  OVX alone had no effect on protein levels of HSP72 in adipose tissue. 
Neither the HFD nor OVX resulted in alterations in HSP72 protein expression in the 
soleus or EDL muscles (data not shown).   
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Figure 8. HFD increases stress kinase activation and decreases HSP72 expression in 
adipose tissue.  pJNK/total JNK (A), IκBα (B), and HSP72 (C) protein levels were 
measured by Western blot analysis.  Both the 46 kDa and 54 kDa bands were quantified for 
pJNK and JNK. Non-phosphorylated protein levels were normalized to total protein 
measured by Ponceau staining. Values are means + SE for 5-6 samples per group.  *P<0.05 
vs. chow sham; #P<0.05 vs. chow OVX. 
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DISCUSSION   
The purpose of the current study was to examine the effects of a HFD on adipose 
tissue and skeletal muscle glucose metabolism in female rats with and without OVX, and 
to determine whether modulation of glucose metabolism in response to a HFD could be 
attributed to alterations in ER expression. While a short-term HFD in female rats induced 
whole body glucose intolerance, tissue specific effects were isolated to the adipose tissue 
with no observed differences in insulin-stimulated glucose uptake, GLUT4, or ERα 
protein expression levels in skeletal muscle. GLUT4 protein decreased dramatically in 
adipose tissue of OVX and sham treated rats as a result of a HFD, as did expression of 
ERα, the ER isoform previously shown to positively mediate glucose metabolism (Barros 
et al. 2006b; Muraki et al. 2006; Barros et al. 2009). Increased stress kinase activation 
and decreased HSP72 expression in adipose tissue in response to a HFD further 
demonstrates the impact of high-fat feeding on this tissue. These new findings highlight 
the differential effects of high-fat feeding in female compared to male rats, with previous 
studies demonstrating a significant decrease in skeletal muscle glucose metabolism in 
response to a HFD in male rats (Pedersen et al. 1991; Han et al. 1995; Zierath et al. 1997; 
Tremblay et al. 2001; Gupte et al. 2009a).  In addition, our findings suggest a high-fat 
diet induced loss of ERα in adipose tissue may be a contributing factor in the 
pathogenesis of glucose intolerance in female rats. 
Ribas et al. (Ribas et al. 2009) recently showed that female ERα knockout mice 
have decreased whole body glucose tolerance compared to wild-type mice, suggesting 
that the absence of ERα results in decreased glucose metabolism. While this data 
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indicates that ERα is critical for the maintenance of whole body insulin action, the effect 
of a HFD on ER expression in insulin responsive tissue was unknown. Our findings 
reveal that ERα expression was decreased with a HFD only in the adipose tissue, which 
also displayed decreased GLUT4 protein and likely reflects lower glucose utilization in 
this tissue. OVX animals fed a chow diet demonstrated decreased ERα without 
corresponding changes in GLUT4, whole body glucose tolerance, or markers of 
inflammation. While the role of ERα in mediating glucose metabolism cannot be firmly 
established from this data, these findings suggest ERα-mediated effects may be 
dependent on additional changes induced by the HFD (stress kinase activation and HSP 
expression changes). In contrast, in the insulin-responsive skeletal muscle tissue, ERα 
expression was unchanged as was glucose uptake and GLUT4 protein expression levels. 
It is still possible that in insulin-resistant skeletal muscle (such as that from male rats fed 
a HFD), alterations in ERα expression could occur and contribute to changes in glucose 
metabolism. Other data support our findings of an adipose tissue specific effect of the 
HFD in female rats. For example, Riant et al. (Riant et al. 2009) demonstrated that the 
combination of a HFD and OVX resulted in decreased glucose utilization in adipose 
tissue with no changes in soleus or EDL muscles in female mice (these investigators did 
not assess ER expression changes). Our findings of decreased ERα in adipose tissue in 
the current study support the idea that ERα is the primary functioning ER in adipose 
tissue (Barros et al. 2009). In turn, ERβ has been suggested as the primary functioning 
ER in skeletal muscle (Barros et al. 2009), which is coincident with our findings of 
decreased ERβ in the soleus muscle in response to a HFD. Decreased ERβ, the ER 
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isoform suggested to have a suppressive role on GLUT4 expression (Barros et al. 2006b), 
could result in protection from HFD-induced insulin resistance in skeletal muscle. The 
effects of estrogen on skeletal muscle likely depend on the balance between the two 
receptors and future studies are needed to determine the regulatory roles of ERs in 
skeletal muscle. 
Barros et al. (Barros et al. 2006b; Barros et al. 2009) have previously shown that 
ERs modulate GLUT4 expression in adipose tissue and skeletal muscle. Although the 
potential mechanism has yet to be demonstrated in skeletal muscle, ERα could modulate 
GLUT4 expression through specificity protein 1 and nuclear factor-kappa B. Ribas et al. 
did not find a decrease in skeletal muscle GLUT4 expression in ERα knockout mice 
despite insulin resistance and decreased glucose uptake in these mice (Ribas et al. 2009). 
As these investigators point out, GLUT4 expression is regulated by redundant 
transcriptional pathways and ERα is likely only one of these pathways. However, our 
findings, and others (Barros et al. 2009) seem to suggest that ERα modulation of GLUT4 
occurs primarily in the adipose tissue and future studies will be needed to assess 
transcriptional control of GLUT4 by ERα in adipose tissue.  
Estrogen has the potential to regulate fat storage and triacylglyceride 
accumulation by altering transcription of lipogenic proteins such as SREBP-1 and its 
downstream targets, ACC, and FAS (D'Eon et al. 2005; Bryzgalova et al. 2006; Paquette 
et al. 2007; Jiang et al. 2009; Chen et al. 2010). The effects of estrogen on lipogenic 
pathways have primarily been assessed in response to estrogen treatment or replacement. 
For example, Phrakonkham et al. (Phrakonkham et al. 2008) demonstrated that estrogen 
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treatment increased FAS expression in cultured adipocytes. However, other studies have 
demonstrated opposite effects, with estrogen treatment in mice shown to decrease ACC 
and FAS mRNA in adipose tissue (D'Eon et al. 2005; Bryzgalova et al. 2008). As has 
been previously shown, physiological estrogen levels may positively modulate glucose 
metabolism while high or low estrogen levels have a different effect (Muraki et al. 2006; 
Nagira et al. 2006). More studies are needed to assess the role of estrogen and ER 
expression in modulating lipogenic pathways in cycling, OVX and estrogen- treated 
animals.  
Increased lipid intermediates and oxidative stress in insulin-responsive tissues can 
result in activation of stress kinases (Yuan et al. 2001; Hirosumi et al. 2002; Ropelle et al. 
2006; Gupte et al. 2009a; Gupte et al. 2009b). We (Gupte et al. 2009a; Gupte et al. 
2009b) and others (Chung et al. 2008; Ribas et al. 2009) have previously shown that 
increased stress kinase activation and decreased HSP expression contribute to decreased 
insulin signaling and glucose uptake in skeletal muscle. Further evidence suggests that 
ERα may be involved in stress kinase activation and HSP expression. Ribas et al. 
demonstrate increased activation of JNK in skeletal muscle and adipose tissue of ERα 
knockout mice (Ribas et al. 2009). When challenged with a HFD, ERα knockout mice 
display greater JNK activation and decreased HSP72 expression in adipose tissue 
compared to high-fat fed wild-type mice (Ribas et al. 2009). These data suggest that ERα 
may contribute to glucose regulation by positively modulating stress kinase activation 
and HSP expression. Evidence of inflammation, increased stress kinase activation 
(increased pJNK and decreased IκBα), and decreased HSP72 expression in adipose tissue 
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was observed in the present study, although these changes did not always correlate with 
changes in ERα levels. With OVX alone, ERα protein was decreased in adipose tissue 
without changes in inflammation observed with a HFD (increased stress kinases and 
decreased HSP72). As OVX alone did not result in increased adiposity or glucose 
intolerance, it is possible the combination of decreased ERα and increased inflammation, 
as observed with the HFD, is critical for glucose intolerance. These results indicate the 
complex interplay of diet, hormones and inflammation in insulin-responsive tissue 
requiring further investigation.  
While this study focuses on the effect of a HFD and OVX on adipose tissue and 
skeletal muscle glucose metabolism, the liver is also an important regulator of glucose 
metabolism. In ERα knockout mice, modest hepatic insulin resistance is present as 
demonstrated by elevated hepatic glucose production during insulin stimulation and 
decreased insulin receptor substrate-PI 3-kinase p85 association compared to wild type 
mice (Ribas et al. 2009). Plausibly, ERα knockouts could have impaired signal transducer 
and activator of transcription 3 (STAT3) function. Estrogen treatment upregulates 
STAT3, which suppresses key enzymes in glucose homeostatis, including the 
gluconeogenic genes glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate 
carboxykinase (PEPCK) (Gao et al. 2006; Lundholm et al. 2008; Ramadoss et al. 2009). 
Future studies are needed to assess the effects of OVX and a HFD on ER protein 
expression in the liver and their role in regulating hapatocyte substrate metabolism.  
While previous studies demonstrate the importance of the ERs in regulating 
glucose metabolism, the impact of a HFD on ER expression in skeletal muscle and 
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adipose tissue was unknown. Findings from the present study indicate a short-term HFD 
in female rats induced whole body glucose intolerance, along with decreased ERα and 
GLUT4 in adipose tissue. In contrast with previous findings using male rodents, a short-
term HFD did not decrease skeletal muscle glucose uptake in female rats. In addition, 
decreased ERβ expression was observed in the soleus muscle with no changes in skeletal 
muscle ERα expression. Future studies are needed to determine the tissue specific 
regulation of ERs and how altered ER expression and/or function may contribute to 
increased susceptibility to type 2 diabetes.  
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Abstract 
Previous studies suggest estrogen receptor α (ERα) is involved in estrogen-
mediated regulation of glucose metabolism and is critical for maintenance of whole body 
insulin action. Despite this, the effect of direct ERα modulation in insulin-responsive 
tissues is unknown. The purpose of the current study was to determine the impact of ERα 
activation, using the ER subtype-selective ligand propylpyrazoletriyl (PPT), on skeletal 
muscle glucose uptake. 2 month-old female Sprague Dawley rats, ovariectomized for 1 
week, were given subcutaneous injections of PPT (10 mg/kg), estradiol benzoate (EB; 20 
μg/kg), the ERβ agonist diarylpropionitrile (DPN, 10 mg/kg), or vehicle every 24 hours 
for 3 days. On the fourth day, insulin-stimulated skeletal muscle glucose uptake was 
measured in vitro and insulin signaling intermediates were assessed via Western blotting. 
Activation of ERα with PPT resulted in increased insulin-stimulated glucose uptake into 
the slow-twitch soleus and fast-twitch extensor digitorum longus (EDL) muscles, 
activation of insulin signaling intermediates (as measured by pAkt and PAS) and 
phosphorylation of AMPK.  GLUT4 protein was increased only in the EDL muscle. Rats 
treated with EB or DPN for 3 days did not show an increase in insulin-stimulated skeletal 
muscle glucose uptake compared to vehicle-treated animals. These new findings reveal 
that direct activation of ERα positively mediates glucose uptake and insulin action in 
skeletal muscle. Evidence that estrogens and ERα stimulate glucose uptake has important 
implications for understanding mechanisms of glucose homeostasis, particularly in 
postmenopausal women.   
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Introduction 
Numerous clinical and basic studies demonstrate that estrogens contribute to 
glucose homeostasis (Louet et al. 2004). The beneficial effects of estrogens on insulin 
action and glucose homeostasis are supported by studies showing insulin sensitivity is 
higher in premenopausal women compared with age-matched men (Nuutila et al. 1995; 
Donahue et al. 1997). Following menopause, a significant decline in insulin sensitivity 
occurs along with a corresponding increase in fat mass (Lindheim et al. 1994; Carr 2003; 
Alonso et al. 2006; Moreno et al. 2010). Ovariectomy has also been shown to impair 
insulin sensitivity and glucose metabolism in animal models (Kumagai et al. 1993; 
Wagner et al. 1998). In addition, estrogen replacement can ameliorate the increased risk 
for type 2 diabetes in postmenopausal women and improve whole body (Lindheim et al. 
1994; Margolis et al. 2004; Alonso et al. 2006; Riant et al. 2009; Moreno et al. 2010) and 
skeletal muscle glucose metabolism (Riant et al. 2009; Moreno et al. 2010).  
The physiological actions of estrogens are mediated by two receptors, estrogen 
receptor (ER) α and ERβ. Both ERα and ERβ are expressed in a variety of tissues, with 
ERα more highly expressed in insulin-sensitive tissue (Ribas et al. 2009). Increased 
adiposity occurs in humans and mice as a result of decreased ERα activation (Smith et al. 
1994; Heine et al. 2000), and mice with global knockout of ERα exhibit impaired glucose 
tolerance and skeletal muscle insulin resistance (Heine et al. 2000; Bryzgalova et al. 
2006; Riant et al. 2009). Based on this evidence, the beneficial effects of estrogens on 
glucose metabolism are thought to be mediated by ERα. However, while there is strong 
clinical evidence demonstrating a relationship between ERα expression levels and the 
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incidence of insulin resistance and increased adiposity, the ability of ERα to positively 
mediate insulin action and increase glucose uptake in vivo is unknown.  
The purpose of the current study was to determine the impact of in vivo ERα 
activation on skeletal muscle glucose uptake and insulin action. Skeletal muscle accounts 
for 75% of glucose regulation in the body (DeFronzo et al. 1985) and, as a result, has a 
significant impact on whole body glucose homeostasis. In the current study, we utilized 
estradiol benzoate (EB) and the compound propylpyrazoletriyl (PPT), a potent ERα 
agonist. PPT is capable of binding with high affinity and 400-fold preference to ERα, and 
exhibits almost no binding to ERβ (Stauffer et al. 2000). For comparison, the ERβ agonist 
diarylpropionitrile (DPN), which binds to ERβ at a 70-fold higher affinity than ERα 
(Meyers et al. 2001), was also used. Our results demonstrate that activation of ERα with 
PPT increases insulin-stimulated glucose uptake and insulin signaling in skeletal muscle. 
These findings provide new insight into the role of estrogen receptors in mediating 
glucose uptake, a finding with important implications for postmenopausal women at 
increased risk for type 2 diabetes.  
 
Methods 
Ethical approval 
The authors have read "Reporting ethical matters in the Journal of Physiology: standards 
and advice." (Drummond 2009), and our experiments comply with the policies and 
regulations of The Journal of Physiology and the UK regulations on animal 
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experimentation. All protocols were approved by the Animal Care and Use Committee of 
the University of Kansas Medical Center. 
 
Materials 
GLUT4 antibody (ab654) and tubulin (ab7291) were purchased from Abcam 
(Cambridge, MA). pAkt (S473), total Akt, phospho-(ser-thr) Akt substrate (PAS), pERα 
(S118), pAMPK (T172), and total AMPK were purchased from Cell Signaling 
(Beverly, MA). pAS160 (T642) and total AS160 were purchased from Millipore 
(Billerica, MA). ERα (MC-20) was purchased from Santa Cruz (Santa Cruz, CA) and 
ERβ (PA1-310B) was purchased from Thermo Fisher Scientific (Rockford, IL). Donkey 
anti-rabbit HRP-conjugated secondary antibody was purchased from Jackson (West 
Grove, PA) and goat anti-mouse HRP-conjugated secondary antibody was purchased 
from Bio-Rad (Hercules, CA). Enhanced chemiluminescence reagents were purchased 
from Fisher Scientific (Pittsburg, PA). [14C]mannitol and 2-deoxy-[1,2-3H]glucose were 
purchased from American Radiolabeled Chemicals (St. Louis, MO). Estradiol benzoate 
(E9000; EB) was purchased from Sigma. Propylpyrazoletriyl (PPT) and 
diarylpropionitrile (DPN) were purchased from Tocris Bioscience (Ellisville, MO). All 
other reagents were obtained from Sigma. 
 
Experimental animals and treatment 
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2 month-old female Sprague Dawley rats were purchased from Charles River 
Laboratories (Wilmington, MA) and housed in a temperature-controlled (22 ± 2°C) room 
with 12-h light and dark cycles and given free access to food and water. Animals 
underwent bilateral ovariectomy (OVX) under ketamine/atropine/xylazine anesthesia 
(intraperitoneal injection of 60 mg/kg body wt ketamine, 0.4 mg/kg body wt atropine, 8 
mg/kg body wt xylazine). Bilateral flank incisions were made under aseptic conditions. 
The ovaries were identified and bilaterally removed via cauterization. In a subset of 6 
animals, incisions were made but the ovaries were left intact for evaluation of 
endogenous estradiol levels at sacrifice. Wounds were closed using sutures and wound 
clips. One week following surgery, OVX animals received subcutaneous injections once 
every 24 hours for 3 days (N = 6 animals per group) of EB (20 μg/kg body wt) dissolved 
in 90% corn oil/10% ethanol, PPT (10 mg/kg body wt) dissolved in DMSO, or DPN (10 
mg/kg body wt) dissolved in DMSO. This dose of PPT and DPN has previously been 
used in in vivo rodent studies (Harris et al. 2002; Lee et al. 2005). The dose of EB was 
chosen to produce physiological levels of serum estradiol (Hurn and Macrae 2000; Haim 
et al. 2003). EB is commonly used in research studies and is a conjugate-salt form of 17β-
estradiol. Like all conjugate molecules, the benzoate moiety dissociates from the 17β-
estradiol moiety when dissolved in solution. Thus, the solution of EB injected into the 
animals contains free 17β-estradiol which binds to the ERs. Vehicle treatments were 90% 
corn oil/10% ethanol or DMSO, as appropriate. No differences in uterine weight or 
glucose uptake were observed between the two vehicle treatments, and therefore these 
measurements were combined in the results section. Rats were fasted 10 hours prior to 
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muscle incubation and glucose transport experiments. 24 hours following the final 
injection, the animals were anesthetized with an intraperitoneal injection of pentobarbital 
sodium (2.5 mg/100 g body wt) for removal of the soleus and extensor digitorum longus 
(EDL) muscles. The uterus was also removed and weighed. Rats were sacrificed by 
cervical dislocation.  
 
Muscle incubation 
The soleus and EDL muscles were dissected and each split longitudinally into two strips 
to allow for adequate diffusion of substrates, as described previously (Henriksen and 
Holloszy 1991; Gupte et al. 2008). Two muscle strips per rat were assessed for glucose 
transport and two strips for Western blot analysis. Muscle strips designated for Western 
blot analysis recovered from the dissection for 60 min in flasks containing 2 ml of Krebs-
Henseleit bicarbonate buffer (KHB) with 8 mM glucose, 32 mM mannitol, and a gas 
phase of 95% O2-5% CO2 (recovery medium). The flasks were placed in a shaking 
incubator maintained at 35°C. Following recovery, one muscle strip was transferred to 
recovery medium containing 2 mU/mL insulin, and the other muscle strip was left 
without insulin (basal) in recovery medium for 30 min and then clamp frozen in liquid 
nitrogen.    
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Measurement of glucose transport activity 
Glucose transport was measured in soleus and EDL muscle strips. Muscle strips were 
incubated after dissection in recovery medium for 60 min at 35°C and then rinsed for 30 
min at 29°C in 2 mL of oxygenated KHB containing 40 mM mannitol, with or without 
insulin (2 mU/mL). After the rinse step, muscles were incubated for 20 min at 29°C in 
flasks containing 2 ml KHB with 4 mM 2-[1,2-3H]deoxyglucose (2-DG) (1.5 μCi/mL) 
and 36 mM [14C]mannitol (0.2 μCi/mL), with or without insulin (2 mU/mL), with a gas 
phase of 95% O2-5% CO2 in a shaking incubator. The muscles were then lightly blotted, 
clamp frozen in liquid nitrogen, and processed as described previously (Young et al. 
1986; Geiger et al. 2006) for determination of intracellular 2-DG accumulation (3H dpm) 
and extracellular space (14C dpm) on a scintillation counter. 
 
Serum estradiol measurement 
Blood samples were collected at time of sacrifice and allowed to clot at room temperature 
for 30 minutes. Samples were spun at 17,500 x g for 20 minutes at 4°C. Serum estradiol 
levels were measured by Estradiol E2 Coat-a-Count Assay (Siemens Diagnostics, 
TKE21). 
 
Western blotting 
Muscles incubated with and without insulin and clamp frozen in liquid nitrogen were 
homogenized in a 12:1 (volume-to-weight) ratio of ice-cold buffer from Biosource 
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(Invitrogen, Camarillo, CA) containing 10 mM Tris·HCl (pH 7.4); 100 mM NaCl; 1 mM 
each of EDTA, EGTA, NaF, and phenylmethylsulfonyl fluoride; 2 mM Na3VO4; 20 mM 
Na4P2O77; 1% Triton X-100; 10% glycerol; 0.1% SDS; 0.5% deoxycholate; and 
250μl/5ml protease inhibitor cocktail. Homogenized samples were rotated for 30 minutes 
at 4°C and then centrifuged for 20 minutes at 3,000 rpm at 4°C. The protein 
concentration of the supernatant was determined by the Bradford method (Bio-Rad). 
Samples were prepared in 5X Laemmli buffer containing 100 mM dithiothreitol and 
boiled in a water bath for 5 minutes. Samples analyzed for GLUT4 protein were not 
boiled. Protein (30–100 μg) was separated on a SDS-PAGE (7.5–10%) gel followed by a 
wet transfer to a nitrocellulose membrane for 60–90 minutes (200 mA). Total protein was 
visualized by Ponceau staining, and GLUT4 blots were normalized to the 45kDa band. 
Membranes were blocked for 1 hour at room temperature in 5% nonfat dry milk in Tris-
buffered saline with 0.1% Tween 20 (TBST) and then incubated overnight with the 
appropriate primary antibodies. Antibodies were diluted in 5% nonfat dry milk in TBST 
or in 1% bovine serum albumin in TBST. Blots were incubated in a HRP-conjugated 
secondary antibody in 1% nonfat dry milk in TBST for 1 hour at room temperature and 
visualized by ECL. Western blots first probed for phosphorylated proteins were stripped 
and probed for total protein expression for normalization, and non-phosphorylated 
proteins were stripped and probed for tubulin expression for normalization. Blots were 
stripped for 20 minutes at 55°C in buffer containing 62.5mM Tris-HCl, 2% SDS and 
100mM 2-mercaptoethanol.  Blots were then rinsed three times in TBST for 15 minutes 
each, blocked in 5% milk in TBST for 1 hour, and incubated in the appropriate primary 
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antibody overnight. The GLUT4 antibody only works with non-denatured protein, and 
the tubulin antibody requires denaturation. Therefore, Western blots that were ran with 
non-denatured samples and probed for GLUT4 were not able to be stripped and re-probed 
for tubulin for normalization. Therefore, Ponceau staining, which does not require 
denaturing, was used for normalizing as previously described (Gupte et al. 2008). We 
identified the 56 kDa ERβ protein by using the rat hypothalamus as a positive control 
(Figure 9). This tissue has previously been used as a positive control (Kalbe et al. 2007). 
Bands were quantified using Image J densitometry.  
 
Statistical analysis 
Results are presented as means + SE, and statistical significance was set at P < 0.05. 
Symbols on the uterine weight, pERα, total ERα, pAMPK, and GLUT4 graphs represent 
differences determined by one-way ANOVA. Symbols on the glucose transport, pAkt, 
and PAS-160 graphs represent differences determined by a Student-Newman Keuls post 
hoc test following a significant interaction as determined by two-way ANOVA. 
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Figure 9: ERα protein identified by the hypothalamus.  Female Sprague 
Dawley rat hypothalamus and soleus muscles were homogenized and total 
protein was measured as stated in the materials and methods. ERα protein 
was measured by Western blot analysis. Lane 1 represents the 
hypothalamus (3 μg protein) and lanes 2-9 represents soleus muscle 
samples (100 μg protein). 
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Results 
In vivo effects of estrogen and PPT treatment 
In order to control for endogenous estrogen levels, all animals underwent OVX for 1 
week. At sacrifice, serum estadiol levels were significantly decreased as a result of OVX 
(11.9 + 1.8 pg/mL vs. 6.8 + 0.4 pg/mL for intact and OVX animals, respectively; 
p<0.01). Serum estradiol levels were significantly greater in EB treated animals (14.5 + 
2.0 pg/mL) compared to vehicle treated animals (6.8 + 0.4 pg/mL; p<0.001). Estradiol 
levels for EB treated animals were within physiological values for cycling rodents (Hurn 
and Macrae 2000; Haim et al. 2003).  
Administration of estrogen and PPT has been shown to increase uterine weight by 
activation of ERα (Harris et al. 2002; Frasor et al. 2003; Stygar et al. 2007). In this 
manner, uterine weight can serve as a bioassay for the in vivo effects of estrogen and 
PPT. In OVX female rats, administration of both EB and PPT for 3 days resulted in a 
significant and similar increase in uterine weight compared to vehicle treated controls 
(Figure 8), which suggests that ERα is being activated to the same extent in the uterus. 
Consistent with previous findings (Harris et al. 2002; Frasor et al. 2003), a higher dose of 
PPT than EB was needed to increase uterine weight. In contrast, administration of the 
ERβ agonist DPN for 3 days had no effect on uterine weight (Figure 10) as previously 
shown (Frasor et al. 2003).  
Prior to treatment with EB, PPT, or DPN, body weight was not different among 
groups. After treatment, body weight did not change in animals treated with EB (vehicle 
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179.2 + 3.2 g vs. EB 172.2 + 2.8 g) or DPN (vehicle 184.8 + 3.6 g vs. DPN 181.5 + 2.9 
g) but decreased in animals treated with PPT (vehicle 183.3 + 2.0 g vs. PPT 169.3 + 1.8 
g; p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Administration of EB and PPT activates ERα as indicated 
by an increase in uterine weight.  Female Sprague Dawley rats were give 
subcutaneous injections of EB (20 μg/kg), PPT (10 mg/kg), DPN 
(10mg/kg), or vehicle for 3 days. Uterine weight was measured at time of 
sacrifice. Symbol represents differences determined by one-way ANOVA. 
*p<0.001 vs. vehicle; N = 6/group  
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PPT increases insulin-stimulated glucose transport in soleus and EDL muscle 
To determine the impact of ERα stimulation on skeletal muscle glucose uptake, we 
performed in vitro 2-DG uptake assays on the predominately slow-twitch soleus or the 
predominately fast-twitch EDL muscles following EB, PPT, or DPN administration. 
Insulin-stimulated glucose uptake was significantly increased above basal in all treatment 
groups in both the soleus and EDL muscles (Figure 11A and 11B, respectively). Three 
day treatment with EB did not augment insulin-stimulated glucose uptake compared to 
that observed with vehicle alone. However, specifically activating ERα with PPT resulted 
in a greater increase in insulin-stimulated glucose transport in both the soleus and EDL 
muscles compared to vehicle treated controls. This observed increase in the soleus and 
EDL muscles was 108% and 55%, respectively, greater than insulin-stimulated glucose 
transport in rats treated with vehicle. Treatment with the ERβ agonist DPN had no effect 
on insulin-stimulated skeletal muscle glucose uptake.  
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Figure 11: Skeletal muscle glucose transport in female rats treated 
with vehicle, EB, PPT, and DPN.  Female Sprague Dawley rats were give 
subcutaneous injections of EB (20 μg/kg), PPT (10 mg/kg), DPN 
(10mg/kg) or vehicle for 3 days. Insulin-stimulated glucose transport was 
measured in soleus (A) and EDL (B) muscles as described in the materials 
and methods. Briefly, muscles were incubated in the absence of insulin 
(open bars) or in the presence of insulin (2 mU/ml, solid bars), along with 
2-[1,2-3H]deoxyglucose. *p<0.001 and †p<0.05 vs. insulin-stimulated 
vehicle indicates a significant interaction as determined by two-way 
ANOVA. The horizontal line indicates a significant main effect of insulin 
relative to basal across all treatment groups, #p<0.05; N = 6/group. 
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PPT activates ERα in skeletal muscle 
Given the significant effect of PPT on skeletal muscle glucose uptake, we next 
investigated the cell signaling pathways altered by PPT in skeletal muscle. 
Phosphorylation of ERα, a measure of protein activation (Weigel 1996; Joel et al. 
1998), significantly increased in soleus and EDL muscles (Figures 12C and 12D, 
respectively) following 3 days of PPT administration compared to vehicle-treated 
controls. Total ERα also decreased following PPT treatment (Figures 12C and 12D). No 
change in ERβ occurred in soleus or EDL muscles as a result of PPT treatment (Figures 
12C and 12D), highlighting the specificity of PPT for ERα in skeletal muscle. 
 
PPT increases insulin-stimulated phosphorylation of Akt and AMPK in soleus and 
EDL muscle 
Akt is a protein kinase in the insulin/IRS-1/PI3K signaling cascade, and activation of this 
protein is crucial for insulin-stimulated glucose transport. Our results demonstrate that 
activation of Akt in response to insulin stimulation, as measured by phosphorylation of 
Akt on serine 473, was increased in the soleus and EDL muscles from rats treated with 
PPT (Figures 13A and 13B). An additional pathway for signaling GLUT4 translocation 
to the membrane and increasing glucose transport, independent of insulin, is by 
phosphorylation of AMP-activated protein kinase (AMPK). PPT treatment resulted in 
increased phosphorylation of AMPK in both the soleus and EDL muscles (Figures 13C 
and 13D, respectively).    
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Figure 12: PPT activates ERα in skeletal muscle.  Female Sprague 
Dawley rats were given subcutaneous injections of PPT (10 mg/kg) or 
vehicle for 3 days. Western blot analysis measured phosphorylation of ERα 
normalized to total ERα and total ERα and total ERβ normalized to tubulin 
in the soleus (C) and EDL (D) for vehicle (open bars) and PPT-treated 
(closed bars) animals. Representative blots are shown for the soleus (A) 
and EDL (B). *p<0.05 and †p<0.01 vs. vehicle as determined by one-way 
ANOVA; N = 6/group  
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Figure 13: In vivo activation of ERα via PPT increases insulin-stimulated 
phosphorylation of Akt and AMPK in the soleus and EDL.  Female Sprague Dawley rats 
were treated with PPT as stated in the materials and methods. Activation of Akt was 
measured by Western blot analysis of pAkt normalized to Akt in the absence of insulin 
(open bars) or in the presence of insulin (2 mU/ml, solid bars) in the soleus (A) and EDL 
(B). *p<0.01, †p<0.001 on (A) and (B) vs. insulin-stimulated vehicle indicates a significant 
interaction as determined by two-way ANOVA. The horizontal line indicates a significant 
main effect of insulin relative to basal, #p<0.05. Activation of AMPK was measured by 
Western blot analysis of pAMPK normalized to total AMPK in the soleus (C) and EDL (D). 
Symbols on (C) and (D) represent differences determined by one-way ANOVA. *p<0.01, 
‡p<0.05 vs. vehicle; N = 6/group.  
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PPT increases insulin-stimulated phosphorylation of PAS-160 in soleus and EDL 
muscle 
Activation of Akt and AMPK results in downstream activation of Akt substrates with a 
molecular weight of 160 kDa, including AS160. Detection of activated Akt substrates can 
collectively be identified by a phospho-Akt substrate (PAS) antibody. Activation of Akt 
substrates with a molecular weight of 160 kDa (PAS-160) in response to insulin 
stimulation was increased in the soleus and EDL muscles from rats treated with PPT 
(Figures 14A and 14B). We measured specific activation of AS160 by phosphorylation of 
threonine 642 and found no additional increase in insulin-stimulated activation in the 
soleus and EDL muscles from rats treated with PPT compared to rats treated with vehicle 
(Figures 14C and 14D).  
 
PPT increases GLUT4 protein in the EDL muscle 
Insulin and AMPK both signal translocation of GLUT4 to the cell membrane where 
GLUT4 then transports glucose into the cell. Rats treated with PPT demonstrated 
increased GLUT4 protein levels in EDL muscles (Figure 15B). In contrast, GLUT4 
protein was unaltered in response to PPT in soleus muscles (Figure 15A). GLUT4 levels 
were not altered as a result of EB or DPN treatment (Figure 15C-15F). 
87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
55 kDa 
160 kDa 
Tubulin 
PAS-160 
A 
SOLEUS 
55 kDa 
160 kDa 
Tubulin 
PAS-160 
B 
EDL 
160 kDa 
160 kDa 
AS160 
pAS160 
C 
160 kDa 
160 kDa 
AS160 
pAS160 
D 
Figure 14: In vivo activation of ERα via PPT increases insulin-stimulated phosphorylation 
of PAS-160 in the soleus and EDL.  Female Sprague Dawley rats were treated with PPT as 
stated in the materials and methods. Downstream activation of Akt and AMPK was measured by 
Western blot analysis of PAS-160 normalized to tubulin (A, B) and pAS160 normalized to total 
AS160 (C, D) in the absence of insulin (open bars) or in the presence of insulin (2 mU/ml, solid 
bars) in the soleus (A, C) and EDL (B, D). *p<0.05 vs. insulin-stimulated vehicle indicates a 
significant interaction as determined by two-way ANOVA. The horizontal lines indicates a 
significant effect of insulin relative to basal, #p<0.05; N = 6/group.   
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Figure 15: In vivo activation of ERα via PPT increases GLUT4 protein in the EDL muscle.  
Female Sprague Dawley rats were treated with PPT, EB, or DPN as stated in the materials and 
methods. GLUT4 was measured by Western blot analysis and normalized to total protein as 
measured by Ponceau staining in animals treated with PPT (A and B), EB (C and D), and DPN (E 
and F). Symbol represents differences determined by one-way ANOVA. *p<0.05 vs. vehicle; N = 
6/group  
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Discussion 
The purpose of the current study was to determine the effect of direct ERα 
modulation on skeletal muscle glucose uptake. While studies utilizing ERα-deficient 
mice demonstrate impaired glucose tolerance in the absence of ERα (Heine et al. 2000; 
Bryzgalova et al. 2006; Riant et al. 2009), in vivo activation of ERα in control female 
rodents had not previously been tested. Three day treatment with PPT, a specific agonist 
of ERα resulted in increased glucose uptake and activation of Akt, PAS-160, and AMPK 
in both soleus and EDL muscles. In addition, activation of ERα resulted in increased 
GLUT4 protein in the EDL muscle. This new evidence of the ability of short-term 
modulation of ERα to increase glucose uptake has important implications for 
understanding the regulation of glucose uptake, particularly in postmenopausal women.  
In a previous study by Ribas et al. (Ribas et al. 2009), ERα knockout mice 
demonstrated impaired glucose tolerance and reduced insulin sensitivity in liver and 
skeletal muscle while on a normal chow diet. The decrease in glucose disposal rate in the 
knockout mice was attributed primarily to impaired insulin action in skeletal muscle. This 
is in contrast to a study by Bryzgalova et al. (Bryzgalova et al. 2006) that attributed 
deceased glucose tolerance in ERα knockout mice primarily to the liver. Our current 
findings demonstrating a dramatic increase in insulin-stimulated skeletal muscle glucose 
uptake in control animals treated with the ERα agonist PPT support the idea that ERα 
plays an important role in skeletal muscle insulin sensitivity. Using ER-subtype specific 
ligands is an alternative and complementary approach to using knockout animals. It is 
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encouraging that both methods demonstrate an important role for ERα in mediating 
skeletal muscle insulin sensitivity.   
To our knowledge, only one previous study has looked at the effect of PPT on 
glucose uptake in skeletal muscle. In this study, ob/ob mice were treated with PPT for 7 
days prior to measurement of insulin-stimulated glucose uptake (Lundholm et al. 2008). 
In contrast with the current study, there was no increase in soleus or EDL muscle glucose 
uptake in ob/ob mice treated with PPT. This difference can most likely be attributed to 
the lower dose of PPT used in the previous study (1mg/kg body weight vs. 10 mg/kg 
body weight). Further, the use of hyperglycemic and hyperinsulinemic ob/ob mice in the 
previous study is markedly different from the control OVX rats used in the current study. 
Additional experiments will be needed to determine the ability of a higher dose of PPT to 
improve insulin sensitivity in insulin resistant or type 2 diabetes animal models.  
Estrogen and PPT have been shown to potentiate the insulin signaling pathway 
and increase glucose transport in adipocytes in culture (Muraki et al. 2006; Nagira et al. 
2006) and estrogen has been shown to increase phosphorylation of Akt (Vasconsuelo et 
al. 2008) and AMPK (D'Eon et al. 2008) in C2C12 muscle cells.  In the first study to test 
the effects of estrogen on skeletal muscle in vitro, acute incubations (5 and 10 min) with 
estrogen increased phosphorylation of Akt, AMPK and TBC1D1/4 in soleus muscle 
(Rogers et al. 2009). However, incubation in estrogen for 10 minutes did not increase 
insulin-stimulated glucose transport. Our findings show that 3 days of estrogen treatment 
in vivo also had no effect on insulin-stimulated glucose uptake in soleus or EDL muscles. 
These findings are the first to show that both in isolated rodent skeletal muscle and 
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following in vivo administration, acute estrogen treatment did not produce a measurable 
increase in skeletal muscle glucose uptake. This may be due to the specific expression 
pattern and activation of ERs in skeletal muscle.  
Previous studies indicate that estrogens and estrogen receptor modulators will 
produce a distinct phenotype in cells that express predominately ERα compared to those 
expressing predominantly ERβ (Kian Tee et al. 2004). A number of studies suggest that 
ERα is more highly expressed in insulin sensitive tissues (Deroo and Korach 2006; 
Heldring et al. 2007), and this expression pattern was also recently demonstrated in 
mouse skeletal muscle (Ribas et al. 2009; Baltgalvis et al.). In contrast, Barros et al. 
(Barros et al. 2009) suggest that ERβ expression predominates in skeletal muscle, 
although these investigators primarily focused on nuclear ER expression and the results 
were not quantified. ERα and ERβ are known to demonstrate a complex inter-regulatory 
relationship that varies with the target tissue. For example, activation of ERα can oppose 
the action of ERβ and act as a negative regulator in glucose metabolism (Matthews and 
Gustafsson 2003; Barros et al. 2006a; Barros et al. 2006b). As estrogen activates both 
ERs, the lack of an effect of estrogen on skeletal muscle glucose uptake in the present 
study could be due to ERβ activation off-setting any stimulation of ERα via estrogen. As 
DPN administration did not decrease insulin-stimulated glucose uptake in the present 
study, stimulation of both ERα and ERβ by estrogen could prevent direct activation of 
ERα due to the unique active conformation formed between estrogen and these two 
receptors. In addition to the interregulatory actions of the ERs on each other, estrogen and 
estrogen receptor modulators exert distinct tissue-specific effects by recruiting different 
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coregulatory proteins to ERs (Shang and Brown 2002; Kian Tee et al. 2004). This 
difference in coregulatory protein recruitment can result in a modulator having agonist or 
antagonist properties. The specific coregulatory proteins involved in ERα activation by 
PPT and estrogen in skeletal muscle have yet to be identified. Previous studies have 
shown that long-term estrogen treatment can improve whole body and skeletal muscle 
glucose metabolism in animals fed a high-fat diet or as a result of aging (Riant et al. 
2009; Moreno et al. 2010). Aging or metabolic disease could alter the ratio of ERα to 
ERβ in skeletal muscle and change the tissue response to estrogen and estrogen receptor 
modulators. Future studies are needed to determine the impact of insulin resistance, and 
subsequent chronic estrogen treatment, on ER expression and activation patterns in 
skeletal muscle. 
In the current study, PPT increased ERα phosphorylation in skeletal muscle 
relative to total ERα, while total ERα expression was decreased compared to vehicle-
treated controls. Phosphorylation of ERα may occur in the cytoplasm or the nucleus and 
is important for receptor dimerization and DNA binding (Arnold et al. 1995a; Arnold et 
al. 1995b). However, the extent to which phosphorylation of ERα contributes to the 
involvement of ERα in cell signaling cascades is unknown, and little is known regarding 
the effect of PPT on phosphorylation of ERα. To our knowledge, this is the first report of 
ERα activation and expression characterized in skeletal muscle as a result of PPT 
treatment. Studies thus far have mainly focused on estrogen’s phosphorylation of ERα. 
Phosphorylation on tyrosine residues likely represents basal phosphorylation of ERα in 
the absence of estrogen  (Migliaccio et al. 1986; Arnold et al. 1995a), and activation of 
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ERα results in phosphorylation of serine residues (Washburn et al. 1991; Weigel 1996). 
Specifically, Joel et al. reports that estrogen treatment in MCF-7 cells results in increased 
phosphorylation on Ser118 (Joel et al. 1998). In addition, mutation of Ser118 resulted in 
a 40% reduction in transactivation activity in response to estrogen (Le Goff et al. 1994). 
We chose to assess Ser118 due to a more recent report showing increased 
phosphorylation of ERα on Ser118 in the soleus muscle due to resveratrol treatment, 
which resulted in enhanced glucose uptake (Deng et al. 2008).  
In contrast to the previously mentioned studies on ERα phosphorylation, the 
present study used PPT as an ERα agonist. In MCF-7 cells, Joel et al. demonstrated an 
increase in estrogen-stimulated pERα on Ser118 relative to total ERα, with no decrease in 
total ERα (Joel et al. 1998). In contrast, while our study in rat skeletal muscle 
demonstrates an increase in PPT-stimulated pERα on Ser118 relative to total ERα, we 
also saw a decrease in total ERα. In fact, more recent reports demonstrate that 
phosphorylation of ERα on Ser118 leads to protein degradation of ERα (reviewed in 
(Murphy et al. 2011)). Ultimately, our study demonstrates that of the total ERα present, 
more ERα is phosphorylated on Ser118 in the PPT treated animals than in the vehicle 
treated animals. A recent study by Baltgalvis et al. (Baltgalvis et al. 2010) demonstrated 
that one week of OVX resulted in an increase in ERα gene and protein expression 
compared to sham-treated animals. Two days of estradiol treatment in OVX female mice 
in this same study resulted in a decrease in ERα levels, similar to our results with PPT. In 
addition, we have recently shown that ER protein levels are altered in the skeletal muscle 
and adipose tissue in response to OVX and a high-fat diet (Gorres et al. 2011a). The 
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specificity of PPT for ERα in skeletal muscle is further demonstrated by the lack of effect 
of PPT on ERβ expression. In addition to regulation of ERα by phosphorylation, 
localization of ERα proteins (nuclear, cytosolic, membrane-associated) could also play an 
important role in activation and regulation in response to PPT and should be pursued in 
future studies.  
PPT also results in direct activation of the insulin signaling pathway as shown by 
increased phosphorylation of Akt. To our knowledge, this is the first evidence of the 
effects of PPT on insulin signaling. In support of our findings, stimulation of the insulin 
signaling pathway with resveretrol in C2C12 myotubes was shown to be dependent on 
ERα activation (Deng et al. 2008). Phosphorylation of AS160 on threonine 642 is 
commonly used to assess activation of AS160 and, hence, activation of the insulin 
signaling pathway downstream of Akt. Our results indicate that rats treated with PPT 
have increased insulin-stimulated phospho-Akt substrate (PAS), but not as a result of a 
significant increase in pAS160 on threonine 642. The PAS immunoreactivity at 160 kDa 
includes both AS160 and a paralog of AS160, TBC1D1. As a result, an additional site of 
phosphorylation on AS160 or the TBC1D1 protein could be activated with PPT and 
result in increased glucose transport.   
Specific activation of ERα in vivo with PPT results in increased pAMPK in soleus 
and EDL muscles. In support of this finding, ERα-KO mice demonstrate decreased 
pAMPK in skeletal muscle (Ribas et al. 2009). Furthermore, skeletal muscle simulated 
with estrogen in vivo and in vitro can increase AMPK activation (D'Eon et al. 2008; Riant 
et al. 2009; Rogers et al. 2009), with a recent study showing estrogen-induced AMPK 
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activation is mediated by ERα (Rogers et al. 2009). Together, these findings suggest that 
ERα acts as a positive modulator of AMPK activation. AMPK activation can result in 
increased basal glucose transport, an effect that was not observed in the present study. 
The amount of AMPK phosphorylation may have been insufficient to alter basal glucose 
uptake in the present study. AMPK can phosphorylate both AS160 (Treebak et al. 2006; 
Chen et al. 2008) and TBC1D1 (Geraghty et al. 2007; Pehmoller et al. 2009), although 
with phospho-specific sites distinct from those activated by Akt, to stimulate an increase 
in glucose uptake. This potential for differential regulation has important implications for 
the regulation of glucose uptake and will need to be further explored in the context of 
ERα activation.  
 The ERs have been shown to be involved in modulation of GLUT4 transcription, 
with ERα acting as a positive modulator and ERβ acting as a negative modulator (Barros 
et al. 2006a; Barros et al. 2006b; Barros et al. 2009). Barros et al. (Barros et al. 2006a) 
have proposed a mechanism by which ERα could bind to nuclear factor-kappa B (NF-
κB), a transcription factor with the potential to repress GLUT4 expression. The binding 
of ERα to NF-κB could inhibit this transcription factor’s repression of GLUT4 and 
thereby increase GLUT4 expression. Without ERα present, GLUT4 is decreased in the 
gastrocnemius muscle of male ERα knock-out (ERα-KO) mice (Barros et al. 2006b). 
However, a more recent report shows that female ERα-KO mice do not have decreased 
GLUT4 in the quadriceps or soleus muscle (Ribas et al. 2009). In the current study, 
activation of ERα resulted in increased GLUT4 in the EDL (fast-twitch) but not in the 
soleus (slow-twitch), which suggests that the ability of ERα to regulate GLUT4 may be 
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fiber type specific. As we measured total GLUT4 protein levels, we do not know if the 
increase in GLUT4 in the EDL contributed to the increase in insulin-stimulated glucose 
uptake. It is possible that the increase in total GLUT4 did not contribute to an increase in 
GLUT4 at the membrane or in glucose transport. If so, then this would explain the 
disparity between the soleus and EDL GLUT4 and glucose transport data. However, as 
GLUT4 is an important protein for insulin-stimulated glucose uptake, it is important to 
understand factors which modulate GLUT4, and the ability to modulate GLUT4 by direct 
ERα activation has not previously been shown. While numerous transcriptional pathways 
regulate GLUT4 (Murgia et al. 2009), acute ERα activation may be an additional 
mechanism for modulating GLUT4.  
 A recent study reported that 8 weeks of OVX increased circulating glycerol, 
NEFA, and glucose, and estrogen treatment reversed this (Wohlers and Spangenburg 
2010). While long-term OVX and estrogen treatment had significant systemic metabolic 
effects, it is unlikely that one week of OVX or 3 days of PPT treatment resulted in 
significant changes in plasma glucose, insulin, or lipids, although we did not measure 
these factors in the current study. We think the PPT effects demonstrated in this study are 
a result of acute changes in signaling and protein expression in the skeletal muscle, 
although future studies will be needed to confirm a lack of systemic effect on plasma 
glucose, insulin, and lipid levels. In addition, the decrease in body weight with PPT 
treatment suggests that ERα activation may affect body weight and metabolism. These 
factors may also play an important role in increasing skeletal muscle glucose uptake and 
insulin signaling and will be addressed in future studies.  
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In summary, our study demonstrates that the ERα agonist PPT results in increased 
insulin-stimulated glucose uptake into the skeletal muscle via potentiating the insulin 
signaling pathway, activating AMPK, and increasing GLUT4 protein. Specific activation 
of ERα may provide an additional means by which drug treatments can be developed that 
have a positive impact on glucose metabolism. Future studies are needed to determine the 
long term effects of estrogens, insulin resistance and type 2 diabetes on ER expression 
and activation in skeletal muscle.  
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ABSTRACT 
Clinical evidence demonstrates that many women gain weight following 
menopause. This increase in body weight is accompanied by an increase in abdominal 
adipose tissue. These studies are supported by animal models of ovariectomy (OVX) in 
which removal of the ovaries results in increased total body weight and fat pad weight. 
Previous animal studies demonstrate that estrogen treatment following OVX can decrease 
triacylglyceride accumulation via decreasing expression of proteins in the lipogenic 
pathway. However, as estrogen may exert its effects via various receptors, the mechanism 
of estrogen’s action is unknown. The purpose of the current study was to determine the 
effects of in vivo estrogen receptor α (ERα) activation on body weight regulation, de novo 
fatty acid synthesis, and lipolysis. Ovariectomized 3 month-old female Sprague Dawley 
rats were given subcutaneous injections of propylpyrazoletriyl (PPT; 10 mg/kg) or 
vehicle (DMSO) every 24 hours for 3 days. In vivo activation of ERα with PPT resulted 
in decreased body weight and adipose tissue weight and decreased proteins involved in 
de novo fatty acid synthesis such as acetyl-CoA carboxylase (ACC) and fatty acid 
synthase (FAS). Furthermore, ERα activation increased proteins involved in lipolysis and 
fatty acid uptake in the adipose tissue such as adipose triglyceride lipase (ATGL), 
perilipin, and lipoprotein lipase (LPL). Serum triglycerides, glycerol, and non-esterfied 
fatty acids were unchanged. These findings provide new insight into the role of ERα in 
modulating adipogenesis. Modulation of ERα may represent a powerful tool in the 
prevention of obesity, particularly in postmenopausal women at increased risk for the 
disease.  
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INTRODUCTION  
Ovariectomy (OVX) involves removal of the ovaries in rodents, and this models 
the post-menopausal state. OVX results in increased body weight and adipose tissue 
weight gain (Yakar et al. 2006; Nunez et al. 2007; Nunez et al. 2008; Hong et al. 2009). 
Estrogen is an important regulator of metabolism, and previous animal studies 
demonstrate that estrogen treatment following OVX can decrease adiposity and 
triacylglyceride accumulation via decreasing expression of proteins in the lipogenic 
pathway (D'Eon et al. 2005). However, as estrogen may exert its effects via various 
receptors, the mechanisms of estrogen’s action remain unknown. Estrogen primarily 
mediates its effects by binding to its receptors, estrogen receptor α (ERα) and estrogen 
receptor β (ERβ). The function of these ERs in adipocyte regulation and lipid metabolism 
has not been studied with specific ER activation. 
ERα knock-out (KO) mice have increased body weight, adipose tissue weight, 
and adipocyte size and number compared to wild-type (WT) mice (Heine et al. 2000). 
Similarly, aromatase KO mice, in which androgens cannot be converted to estrogen, have 
increased body weight (Takeda et al. 2003) and adipose tissue weight (Fisher et al. 1998) 
compared to WT mice. In contrast, ERβ KO mice do not have increased adipose tissue 
weight or percent body fat compared to WT mice (Ohlsson et al. 2000). Therefore, 
estrogen/ERα signaling appears to be an important regulator of body weight and 
adipocyte regulation. However, the KO models display the deleterious long-term effects 
of estrogen/ERα deficiency. Studies have not determined if acute ERα activation could 
provide beneficial effects on adipocyte and body weight regulation. We have previously 
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shown that acute ERα activation positively modulates skeletal muscle glucose 
metabolism (Gorres et al. 2011b), and favorable effects may also occur in the adipose 
tissue. 
The purpose of the current study was to determine the effects of in vivo ERα 
activation on body weight regulation, de novo fatty acid synthesis, and lipolysis. We 
administered propylpyrazoletriyl (PPT), a potent ERα agonist, to OVX female rats for 
three days. Our results demonstrate that in vivo activation of ERα decreases body weight 
and adipose tissue weight, as well as proteins involved in de novo fatty acid synthesis. 
Furthermore, ERα activation increased proteins involved in lipolysis in the adipose tissue. 
These findings provide new insight into the role of ERα in modulating adipogenesis. 
Modulation of ERα may represent a powerful tool in the prevention of obesity, 
particularly in postmenopausal women at increased risk for the disease.  
 
MATERIALS AND METHODS 
Materials.  Fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), adipose 
triglyceride lipase (ATGL), and pERα (S118) antibodies were purchased from Cell 
Signaling (Beverly, MA). ERα (MC-20), perilipin (67164), and lipoprotein lipase 
(32885) were purchased from Santa Cruz (Santa Cruz, CA). ERβ (PA1-310B) was 
purchased from Thermo Fisher Scientific (Rockford, IL) and tubulin (ab7291) was 
purchased from Abcam (Cambridge, MA). Donkey anti-rabbit HRP-conjugated 
secondary antibody was purchased from Jackson (West Grove, PA), and goat anti-mouse 
HRP-conjugated secondary antibody was purchased from Bio-Rad (Hercules, CA). 
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Enhanced chemiluminescence reagents were purchased from Fisher Scientific (Pittsburg, 
PA). Propylpyrazoletriyl (PPT) was purchased from Tocris Bioscience (Ellisville, MO). 
All other reagents were obtained from Sigma. 
Experimental animals and treatment.  3 month-old female Sprague Dawley rats 
were purchased from Charles River Laboratories (Wilmington, MA) and housed in a 
temperature-controlled (22 ± 2°C) room with 12-h light and dark cycles and given free 
access to food and water. Animals underwent bilateral ovariectomy (OVX) under 
ketamine/atropine/xylazine anesthesia (intraperitoneal injection of 60 mg/kg body wt 
ketamine, 0.4 mg/kg body wt atropine, 8 mg/kg body wt xylazine). Bilateral flank 
incisions were made under aseptic conditions. The ovaries were identified and bilaterally 
removed via cauterization. Wounds were closed using sutures and wound clips. One 
week following surgery, OVX animals received subcutaneous injections once every 24 
hours for 3 days (N = 6 animals per group) of PPT (10 mg/kg body wt) dissolved in 
DMSO or DMSO. This dose of PPT has previously been used in in vivo rodent studies 
(Harris et al. 2002; Lee et al. 2005). Body weight was measured daily prior to injections. 
Rats were fasted 10 hours prior to sacrifice. 24 hours following the final injection, the 
animals were anesthetized with an intraperitoneal injection of pentobarbital sodium (2.5 
mg/100 g body wt). Tail blood was used to determine glucose levels using a glucometer 
(Accu-Check) prior to tissue dissection. Periuterine white adipose tissue was removed, 
weighed, and frozen in liquid nitrogen. The right soleus and extensor digitorum longus 
(EDL) muscles were also removed and weighed.  
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Serum insulin, triglyceride (TG), glycerol, and non-esterfied fatty acid (NEFA) 
measurement.  Blood samples were collected from the heart at time of sacrifice. Samples 
were placed on ice for at least 30 minutes, then spun at 3,000 rpm for 60 minutes at 4°C. 
The top serum portion was removed for measurement of insulin (Alpco Diagnostics, 80-
INSRT-E01; Salem, NH), triglyceride (Cayman Chemical, 10010303; Ann Arbor, MI), 
glycerol (Sigma, F6428; St. Louis, MO), and NEFA (Wako Diagnostics; Richmond, VA) 
according to the manufacturer’s instructions. 
Western blotting. Adipose tissue was homogenized in a 2:1 (volume-to-weight) 
ratio of ice-cold buffer from Biosource (Invitrogen, Camarillo, CA) containing 10 mM 
Tris·HCl (pH 7.4); 100 mM NaCl; 1 mM each of EDTA, EGTA, NaF, and 
phenylmethylsulfonyl fluoride; 2 mM Na3VO4; 20 mM Na4P2O7; 1% Triton X-100; 
10% glycerol; 0.1% SDS; 0.5% deoxycholate; and 250µl/5ml protease inhibitor cocktail. 
Homogenized samples were rotated for 30 minutes at 4°C and then centrifuged for 20 
minutes at 3,000 rpm at 4°C. The protein concentration of the supernatant was 
determined by the Bradford method (Bio-Rad). Samples were prepared in 5X Laemmli 
buffer containing 100 mM dithiothreitol and boiled in a water bath for 5 minutes. Protein 
(100 µg) was separated on a SDS-PAGE (7.5–10%) gel followed by a wet transfer to a 
nitrocellulose membrane for 60–90 minutes (200 mA). Membranes were blocked for 1 
hour at room temperature in 5% nonfat dry milk in Tris-buffered saline with 0.1% Tween 
20 (TBST) and then incubated overnight with the appropriate primary antibodies. Blots 
were incubated in a HRP-conjugated secondary antibody in 1% nonfat dry milk in TBST 
for 1 hour at room temperature and visualized by ECL. Western blots were stripped and 
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probed for tubulin expression for normalization. Bands were quantified using Image J 
densitometry.  
Statistical analysis.  Results are presented as means + SE. Statistical significance 
was set at P<0.05 and determined by a one-way repeated measures ANOVA or one-way 
ANOVA and Student-Newman-Keuls post hoc test. 
 
RESULTS 
PPT decreases body weight and adipose tissue weight.  Body weight was 
measured on days 1-3, prior to administering the PPT or vehicle, and on day 4, prior to 
sacrifice. Compared to the vehicle treated group, body weight decreased in the animals 
treated with PPT over time, as measured by a one-way repeated measures ANOVA 
(#p<0.001; Figure 16A). The decrease in body weight with PPT treatment paralleled a 
decrease in periuterine adipose tissue weight in the PPT treated group (Figure 16B).  
Skeletal muscle weight did not change in the soleus (Figure 16C) or extensor digitorum 
longus (Figure 16D) muscles with PPT treatment.  
Effects of PPT on fasting blood glucose and serum insulin.  Body weight and 
adipose tissue weight are predictors of fasting blood glucose and serum insulin levels. 
Therefore, we measured fasting blood glucose and serum insulin levels in the vehicle and 
PPT treated animals but found that these values were not different between groups 
(Figures 17A and 17B). 
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Figure 16: PPT decreases body weight and adipose tissue weight.  Female Sprague 
Dawley rats underwent OVX surgery. Seven days post surgery, rats were given PPT 
injections (10mg/kg) or vehicle (DMSO) every 24 hours for 3 days. Body weight (A) 
was measured prior to injections on days 1-3 and prior to sacrifice on day 4. Body 
weight decreased in animals treated with PPT over time, as measured by a one-way 
repeated measures ANOVA (#p<0.001). Periuterine adipose tissue (B), soleus (C), and 
EDL (D) were measured at time of sacrifice. *P<0.01; N = 6 animals per group 
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Figure 17: No change in fasting blood glucose or fasting serum insulin levels.  
Female Sprague Dawley rats underwent OVX surgery. Seven days post surgery, rats 
were given PPT injections (10mg/kg) or vehicle (DMSO) every 24 hours for 3 days. 
Blood was taken at time of sacrifice. N = 6 animals per group 
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PPT activates ERα in the adipose tissue.  Phosphorylation of ERα is a measure 
of protein activation (Weigel 1996; Joel et al. 1998; Deng et al. 2008). PPT significantly 
increased pERα in the adipose tissue (Figure 18A) following 3 days of PPT 
administration compared to vehicle-treated controls. Total ERα decreased following PPT 
treatment (Figure 18B), and no change in ERβ occurred (Figure 18C), highlighting the 
specificity of PPT for ERα in the adipose tissue. 
PPT decreases proteins involved in de novo lipid synthesis in the adipose 
tissue.  The decrease in adipose tissue weight in the PPT treated group may indicate that 
lipogenesis and/or lipolysis are altered in the adipose tissue. ACC and FAS are proteins 
involved in de novo lipid synthesis. In accordance with the decrease in adipose tissue 
weight, PPT treatment significantly decreased ACC and FAS protein levels in the adipose 
tissue (Figures 19A and 19B).  
PPT increases proteins involved in lipolysis and fatty acid uptake in the 
adipose tissue.  While the decrease in factors involved in de novo lipid synthesis likely 
contributes to the decrease in adipose tissue weight with PPT treatment, we also 
measured proteins involved in the regulation of lipolysis, such as ATGL and perilipin. 
PPT treatment significantly increased ATGL and perilipin protein levels in the adipose 
tissue (Figures 20A and 20B). The potential for fatty acid uptake into the adipose tissue 
also increased with PPT treatment, as evident by the increase in LPL (Figure 20C).   
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Figure 18: PPT activates ERα in the adipose tissue.  Female Sprague Dawley rats 
underwent OVX surgery. Seven days post surgery, the rats were given PPT injections 
(10mg/kg) or vehicle (DMSO) every 24 hours for 3 days. Periuterine adipose tissue was 
removed at time of sacrifice. Phosphorylation of ERα was measured by Western blot 
analysis and normalized to total ERα (A). Total ERα (B) and total ERβ (C) were also 
measured and normalized to tubulin.  *P<0.05, #P<0.001; N = 6 animals per group 
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Figure 19: PPT decreases proteins involved in de novo fatty acid synthesis.  Female 
Sprague Dawley rats underwent OVX surgery. Seven days post surgery, the rats were 
given PPT injections (10mg/kg) or vehicle (DMSO) every 24 hours for 3 days. 
Periuterine adipose tissue was removed at time of sacrifice. ACC (A) and FAS (B) 
protein levels were determined by Western blot analysis and normalized to tubulin. 
*P<0.05; N = 6 animals per group 
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Figure 20: PPT increases proteins involved in lipolysis and fatty acid uptake in the 
adipose tissue. Female Sprague Dawley rats underwent OVX surgery.  Seven days post 
surgery, rats were given PPT injections (10mg/kg) or vehicle (DMSO) every 24 hours 
for 3 days. Periuterine adipose tissue was removed at time of sacrifice. ATGL (A), 
perilipin (B), and LPL (C) protein levels were determined by Western blot analysis and 
normalized to actin. *P<0.05, #P<0.001; N = 6 animals per group 
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Effects of PPT on serum TG, glycerol, and NEFA.  As lipolysis in the adipose 
tissue increased in animals treated with PPT, we measured serum TG, glycerol, and 
NEFA levels, which are also indicators of lipolysis. Although there was a trend towards 
decreased serum TG levels with PPT treatment (P=0.08), there were no significant 
differences in serum TG, glycerol, or NEFA levels (Figure 21) between groups.  
 
 
 
 
 
 
 
 
 
 
 
C 
B A P=0.08 
Figure 21: Effect of PPT on serum TG, glycerol, and NEFA.  Female Sprague 
Dawley rats underwent OVX surgery.  Seven days post surgery, rats were given PPT 
injections (10mg/kg) or vehicle (DMSO) every 24 hours for 3 days.  Blood was taken at 
time of sacrifice, and serum TG (A), glycerol (B), and NEFA (C) were measured 
according to the manufactures’ instructions. N = 6 animals per group 
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DISCUSSION 
 The purpose of the current study was to determine the effect of direct ERα 
modulation on body weight and fatty acid metabolism in the adipose tissue. While 
previous studies demonstrate the ability of estrogen to modulate adiposity and be 
protective against high-fat diet-induced obesity (D'Eon et al. 2005; Bryzgalova et al. 
2008; Priego et al. 2008; Wohlers and Spangenburg 2010), the signaling pathway by with 
estrogen acts was previously unknown. We show for the first time that modulation of 
adipogenesis and lipolysis occurs with specific ERα activation. Three day treatment with 
PPT, a specific agonist of ERα resulted in decreased body and adipose tissue weight. In 
addition, proteins involved in de novo lipid synthesis, such as ACC and FAS decreased, 
while proteins involved in lipolysis, such as ATGL and perilipin, increased. This new 
evidence demonstrates the ability of short-term activation of ERα to modulate fatty acid 
metabolism in the adipose tissue. 
Previous studies show that estrogen can modulate body weight and adipose tissue 
weight. In female rats, body weight and adipose tissue weight increased in response to 
high-fat feeding for ten months, and one month of estrogen treatment following this diet 
regime significantly decreased total body weight and adipose tissue weight (Bryzgalova 
et al. 2008). Estrogen can also modulate adiposity in the absence of a HFD, as estrogen 
treatment for 40 days in female mice decreased adipose tissue weight and adipocyte size 
(D'Eon et al. 2005). These beneficial effects of estrogen likely occurred through 
activation of ERα, as our data show that specific ERα activation results in decreased body 
weight and adipose tissue weight.  
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Sex differences exist between males and females with respect to regulation of 
adiposity and fuel partitioning, and the high-fat feeding model has been used to study 
these differences. Priego et al. demonstrate that the response to overfeeding via a high-fat 
diet (HFD) is sex-dependent (Priego et al. 2008). Female rats fed a HFD for six months 
were better protected against the HFD by being able to modulate genes involved in fatty 
acid metabolism to protect against energy overload and decrease lipogenesis. 
Specifically, the female rats were able to up-regulate LPL and decrease ACC and FAS in 
the adipose tissue.  
ACC and FAS are proteins involved in de novo lipid synthesis. ACC catalyzes the 
formation of malonyl CoA from acetyl-CoA, and FAS catalyzes the formation of free 
fatty acids from malonyl CoA (Wakil et al. 1983; Kim 1997).  Our data show that 
specific ERα activation decreases ACC and FAS protein levels, thus contributing to the 
decreased adipose tissue weight. This in agreement with previous studies showing that 
estrogen decreases FAS and ACC in the adipose tissue (D'Eon et al. 2005; Bryzgalova et 
al. 2008). This new information on ERα’s role in fatty acid synthesis provides a means by 
which estrogen may contribute to the sex differences in adipocyte regulation. 
LPL promotes fatty acid uptake into the adipose tissue, and its regulation by 
estrogen remains controversial. D’Eon et al. report that estrogen treatment for 40 days in 
mice decreased LPL gene expression in the adipose tissue, contributing to a decrease in 
fatty acid uptake (D'Eon et al. 2005). However, this treatment method increased LPL and 
proteins involved in lipolysis and energy dissipation in the skeletal muscle, suggesting 
that estrogen also has the ability to promote the use of lipids as fuel. In fact, Priego et al. 
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(Priego et al. 2008) report that LPL protein increased in the adipose tissue of female rats 
in response to a HFD. In contrast, LPL protein levels in males did not increase in the 
adipose tissue when fed a HFD. These sex differences in LPL regulation suggest that 
estrogen may be involved in LPL modulation, with estrogen being able to increase LPL 
in times of need. Our data show that specific ERα activation increased LPL protein levels 
in the adipose tissue. This increased ability for fatty acid uptake was mirrored by an 
increased capability for the fatty acids to undergo lipolysis.   
Lipolysis of triglycerides provides energy from fat stores and involves many steps 
and regulatory proteins. ATGL performs the first step in lipolysis by catalyzing the 
formation of diacylglycerol from triacylglycerol (Jenkins et al. 2004; Villena et al. 2004; 
Zimmermann et al. 2004), which releases a fatty acid for subsequent β-oxidation. This is 
also the rate limiting step in cyclic AMP-dependent protein kinase (PKA)-stimulated 
lipolysis (Kershaw et al. 2006; Miyoshi et al. 2006). Perilipin plays a role in basal 
lipolysis and PKA-stimulated lipolysis. While perilipin inhibits lipolysis in a basal state 
(Martinez-Botas et al. 2000; Tansey et al. 2001), perilipin promotes PKA-stimulated 
lipolysis (Sztalryd et al. 2003; Zhang et al. 2003; Miyoshi et al. 2006). A previous study 
reports that estrogen treatment in mice enhanced epinephrine-stimulated lipolysis by 
increasing levels of perilipin protein (D'Eon et al. 2005). Furthermore, Wohlers et al. 
report that OVX mice have significantly lower perilipin protein levels compared to mice 
with intact ovaries and endogenous estrogen levels, and estrogen treatment in the OVX 
mice restored the protein levels (Wohlers and Spangenburg 2010). Our data are in 
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agreement with these studies and suggest that the estrogen-mediated increase in perilipin 
occur through activation of ERα.  
 Although this study demonstrates that lipolysis increased with ERα activation, no 
changes in serum TG, glycerol, or NEFA occurred. This is in agreement with human 
studies showing that serum TG levels remained unchanged after estrogen or combined 
estrogen/progestin replacement therapy. However, regulation of serum NEFA with 
estrogen treatment remains controversial. While Wohlers et al. report that the decrease in 
adipose tissue weight with estrogen treatment in OVX mice corresponds with a decrease 
in serum glycerol and NEFA levels (Wohlers and Spangenburg 2010), D’Eon et al. report 
that the decrease in adipose tissue weight with estrogen treatment in OVX mice 
corresponds with an increase in serum NEFA levels (D'Eon et al. 2005). In addition, 
estrogen-mediated glycerol release from the adipose tissue was bi-modally regulated: 
estrogen treatment resulted in lower glycerol release under basal conditions and higher 
glycerol release following lipolytic stimulation (D'Eon et al. 2005). We show no change 
in serum glycerol or NEFA levels with acute, specific ERα activation. Therefore, while 
activation of ERα decreases adipose tissue weight and promotes lipolysis in the adipose 
tissue, more studies are needed to ascertain how these changes correspond to alterations 
in circulating NEFA and glycerol levels.   
We previously showed that acute activation of ERα positively modulates skeletal 
muscle glucose metabolism (Gorres et al. 2011b). Similarly, this study demonstrates that 
many changes also occur in the adipose tissue. While we saw a trend towards decreased 
serum TG levels (Figure 6), longer treatment may be needed to see whole body effects of 
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ERα activation. A previous study investigated the long-term effect of PPT treatment in 
ob/ob mice (Lundholm et al. 2008). PPT treatment for 30 days decreased fasting blood 
glucose and improved glucose tolerance, as measured by an intraparitoneal glucose 
tolerance test. However, body weight did not change after PPT treatment. Hepatic lipid 
levels were also measured. While estrogen treatment decreased total lipids, TG, and 
cholesterol, these changes did not occur with PPT treatment.  
In conclusion, our data demonstrate that certain beneficial effects of estrogen on 
adipocyte regulation occur through activation of ERα. Specifically, activation of ERα 
decreased proteins involved in de novo fatty acid synthesis and increased proteins 
involved in lipolysis in the adipose tissue. This resulted in decreased body weight and 
adipose tissue weight. These data provide insight to the previous studies showing sex 
differences in fat storage and the response to high-fat feeding. Furthermore, modulation 
of ERα may represent a powerful tool in the prevention of obesity, particularly in 
postmenopausal women at increased risk for the disease. 
118 
 
 
 
 
 
 
 
Chapter 5 
 
 
 
SUMMARY OF RESULTS AND DISCUSSION 
 
119 
 
Summary of Results. 
 Our studies examined the role of activated ERs in skeletal muscle glucose 
metabolism and adipocyte regulation.  The principle finding and conclusions are as 
follows:  
1. A short-term HFD in female rats resulted in whole body glucose intolerance 
and altered ER expression in the adipose tissue and skeletal muscle.  Most 
effects occurred in the adipose tissue including decreased ERα and GLUT4 
protein levels and increased stress kinase activation.  In the skeletal muscle, 
no changes in insulin-stimulated glucose uptake occurred, as does in male 
rats.  Skeletal muscle changes were limited to a decrease ERβ protein in 
response to OVX and a HFD.  
2. Specific activation of ERα increases insulin-stimulated skeletal muscle 
glucose uptake via potentiating the insulin signaling pathway, increasing 
GLUT4 protein, and increasing activation of AMPK.  Activation of ERβ or 
ERα and ERβ together did not increase skeletal muscle glucose transport.  
These findings suggest that the previously established benefits of E2 on 
glucose metabolism likely occur through activation of ERα.   
3. Specific activation of ERα decreases proteins involved in de novo lipid 
synthesis, periuterine adipose tissue, and body weight and increases proteins 
involved in lipolysis in adipose tissue.  This decrease in adipose tissue weight 
in the abdominal region may also provide benefit to the improved skeletal 
muscle glucose regulation with ERα activation. 
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Discussion. 
 
 
Estrogen versus selective estrogen receptor modulators.   
 
Our findings display the beneficial role of specific ERα activation on skeletal 
muscle glucose uptake and adipocyte regulation.  Yet clinical studies in humans 
(Andersson et al. 1997; Espeland et al. 1998; Kanaya et al. 2003; Margolis et al. 2004; 
Gower et al. 2006) and animal models (Bryzgalova et al. 2008; Riant et al. 2009) 
demonstrate that E2 (which activates both ERα and ERβ) also protects against glucose 
intolerance.  In these animal models, E2 was protective against HFD-induced insulin 
resistance.  Bryzgalova et al. (2008) demonstrated that 9 months of high-fat feeding in 
female mice resulted in the common outcomes including increased body weight, 
increased abdominal adipose weight, increased fasting glucose and insulin levels, and 
decreased whole body glucose tolerance.  However, following 9 months of high-fat 
feeding, 1 month of E2 treatment in conjunction with the high-fat feeding ameliorated the 
outcomes of the HFD.  Riant et al. (2009) found similar results.  As measured by the 
euglycemic-hyperinsulinemic clamp, whole body insulin resistance developed in OVX 
rats fed a HFD for 4 weeks.  However, OVX animals fed the HFD and treated with E2 for 
4 weeks displayed protection against insulin resistance.   
Our data demonstrate that this beneficial effect of E2 likely occurs through 
activation of ERα.  However, our data showed no beneficial effect of E2 on glucose 
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uptake.  This may be due to the fact that our model is markedly different than the high-fat 
feeding models which do demonstrate a beneficial effect of E2 on glucose regulation.  
High-fat feeding may alter the protein levels of the ERs in the body.  This is important 
because E2 activates both ERα and ERβ, and while ERα may have a beneficial effect on 
glucose metabolism, ERβ can oppose the action of ERα and act as a negative regulator in 
glucose metabolism (Matthews and Gustafsson 2003; Barros et al. 2006a; Barros et al. 
2006b).  Prior to our HFD study, the effect of a HFD on ER protein levels was unknown.  
We showed that ERβ expression was significantly decreased in the soleus muscle in 
response to the HFD.  This may allow E2 to primarily activate ERα and provide the 
beneficial effects on glucose regulation.  Therefore, the ratio of ERα to ERβ may be an 
important predictor of the ultimate function of E2 on glucose metabolism.  
  
 
Models used to study E2 and glucose regulation.   
 
Various models are used to study E2 and glucose regulation.  Using animals with 
intact ovaries provides a model of endogenous, cycling hormone levels.  Yet, most 
common in the literature, researchers use OVX animals and administer E2 via injection or 
a time-release pellet.  While this method allows the researchers to control the amount of 
E2 given to each animal, serum E2 levels still fluctuate.  Injections of E2 result in a spike 
of serum E2, which usually peak at 1 hour post injection (Medlock et al. 1991; Zoubina et 
al. 2001), and the E2 fully subsides by 48 hours (Haim et al. 2003).  Time-release E2 
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pellets may be a better choice for delivering a constant dose of E2 for a longer period of 
time.  These pellets usually produce serum E2 levels that peak at around 6 hours, and then 
remain steady for the remainder of the treatment (Medlock et al. 1991).  However, these 
pellets do not provide the physiological cycling of serum E2 levels.  A benefit to giving 
back E2 is that researchers can show the independent effect of E2 on the desired outcome.  
However, altering the E2 level, via OVX and/or E2 replacement may also affect other sex 
hormones, which is generally not measured or taken into account.  In conclusion, the 
outcomes of a study may only pertain to the situation which is modeled.  For example, 
any effect of E2 replacement in an OVX animal may not be the same as what occurs in an 
endogenous, cycling animal.  Furthermore, the rat estrus cycle is 4 days (Westwood 
2008), and the human reproductive cycle is 28 days.  Therefore, the response to 
endogenous, cycling ovarian function may also differ among species. 
The age of the animal being studied is also important to consider.  OVX is 
commonly used to model the post-menopausal state.  However, this procedure is typically 
performed on 2-3 month old rats, which represents early adolescence.  Certainly, using 
rats older than 10 months (when the rat’s reproductive cycle stops) represents the best 
physiological animal model.  However, using older rats comes with its own set of 
challenges and confounding factors.  Aging itself is a risk factor for insulin resistance 
(DeFronzo 1981; Bolinder et al. 1982; Jackson 1990).  In fact, a decline in insulin 
sensitivity begins in the third or fourth decade of one’s life, and it continues to decline 
over one’s lifespan (DeFronzo 1981).  While the exact mechanism of aging’s impact on 
insulin resistance is still being explored, oxidative stress and mitochondrial dysfunction 
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are likely contributors (Short et al. 2005; Asghar and Lokhandwala 2006).  In order to 
assess the independent effect of E2 on glucose metabolism without the factors associated 
with aging, younger animals are commonly used in research studies.  
 The fact that ageing is a risk factor for insulin resistance questions whether the 
decline in insulin sensitivity in females is in fact due to E2 loss or if it is due to the 
increase in oxidative stress and mitochondrial dysfunction.  While the decline in insulin 
sensitivity occurs in men and women, the decrease in insulin sensitivity is more 
pronounced in post-menopausal women compared to age-matched men (Borissova et al. 
2005).  This suggests that menopause in women further impacts the age-associated 
decline in insulin sensitivity. 
 
Adipokines and insulin resistance. 
 
 Adipokines are cytokines secreted from the adipose tissue that can act as an 
autocrine, paracrine, or endocrine hormone.  Increasingly, numerous reports demonstrate 
that adipokines play an important role in insulin resistance via mediating cross-talk 
between adipose tissue and skeletal muscle.  While our studies did not focus on this 
aspect, our data show that PPT impacts both skeletal muscle and adipose tissue.  
Therefore, we must consider the possibility that adipokines are also being modulated and 
may contribute to the changes in skeletal muscle insulin sensitivity.  
 Leptin and adiponectin are two adipokines which improve muscle insulin 
sensitivity (Yamauchi et al. 2001; Singh et al. 2003; Yaspelkis et al. 2004).  These 
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proteins increase fatty acid oxidation and decrease lipid content in the skeletal muscle to 
contribute to the increased insulin sensitivity (Muoio et al. 1997; Minokoshi et al. 2002; 
Steinberg et al. 2002; Tomas et al. 2002; Yamauchi et al. 2002).  Serum adiponectin 
levels are inversely correlated with body mass index (BMI) (Arita et al. 1999), which 
signifies that overweight and obese people have lower adiponectin levels and, hence, 
decreased muscle insulin sensitivity.  In fact, people with T2D have lower serum 
adiponectin levels compared to BMI-matched controls (Hotta et al. 2000). 
 Retinol binding protein 4 (RBP4) is an adipokine which contributes to decreased 
insulin sensitivity, and obesity and T2D results in increased serum RBP4 levels 
(Basualdo et al. 1997; Abahusain et al. 1999; Yang et al. 2005).  Mice fed a HFD also 
have increased serum RPB4 levels (Yang et al. 2005).  Yang et al. (2005) demonstrate 
that the skeletal muscle insulin resistance present in mice with adipose tissue-specific 
GLUT4 KO is due to an increase in RBP4 levels.  Moreover, genetic deletion of RBP4 
enhances insulin sensitivity (Yang et al. 2005).  Thus, RBP4 is an important mediator of 
adipose tissue to skeletal muscle cross talk, with the ability to decrease insulin sensitivity.   
 Very few studies have looked at the possibility of adipokines contributing the 
gender dimorphisms in insulin sensitivity and if E2 may modulate the adipokines. Serum 
adiponectin levels are lower in men than women and in male rats compared to female rats 
(Nishizawa et al. 2002; Gomez-Perez et al. 2008), which may contribute to the fact that 
females are more insulin sensitive than males.  However, there are no differences in 
adiponectin levels between pre- and post-menopausal women or OVX and intact mice 
(Nishizawa et al. 2002; Nunez et al. 2008), but studies show that E2 treatment decreases 
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serum adiponectin levels in mice (Bryzgalova et al. 2008; Riant et al. 2009).  Therefore, 
the role of E2 in modulating adiponectin levels and the potential for this to play a role in 
insulin sensitivity remains unknown.   
In our studies, treating rats for three days with PPT decreased adipogenesis and 
enhanced skeletal muscle insulin sensitivity.  While our data show that the PPT increased 
cell signaling intermediates in the skeletal muscle (e.g. pAkt and pAMPK), we also 
showed that the PPT has an effect on adipocyte regulation.  Therefore, modulation of 
leptin, adiponectin, and RBP4 may also be contributing factors to the observed changes 
in the skeletal muscle.  Future studies are needed to investigate this relationship in detail.    
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Much research in the E2/glucose regulation field has focused on the regulation of 
GLUT4 by the ERs.  While we have shown that in vivo activation of ERα via PPT 
increased GLUT4 protein levels in the EDL muscle, exploring the mechanism by which 
ERα acts to increase GLUT4 is an area that needs future exploration.  
The protein of interest which may link ERα and GLUT4 is NF-κB.  NF-κB is a 
transcription factor activated by stimuli such as cellular stress, cytokines, and 
inflammation.  The promoter region of GLUT4 contains a NF-κB binding site (Long and 
Pekala 1996b), and NF-κB represses GLUT4 transcription (Ruan et al. 2002).  NF-κB 
may be regulated by ERα, as activated ERα can directly bind to NF-κB and decrease NF-
κB–DNA binding (Stein and Yang 1995; Galien and Garcia 1997; Ray et al. 1997; 
Paimela et al. 2007).  This decrease in NF-κB–DNA binding may contribute to the 
increase in GLUT4 with ERα activation.  However, controversy still exists in the field.  
In male ERα KO mice, GLUT4 mRNA and protein is thought to be decreased in the 
gastrocnemius muscle (slow- and fast-twitch fibers) (Barros et al. 2006b).  Yet, in female 
ERα KO mice, GLUT4 mRNA and protein is unchanged in the quadriceps (slow- and 
fast-twitch fibers) and soleus (primarily fast-twitch fibers) muscles (Ribas et al. 2009).  
We too see differences in GLUT4 protein levels based on the muscle and fiber-type 
examined.  While GLUT4 increased in the EDL (primarily fast-twitch fibers) with ERα 
activation, no change in GLUT4 was present in the soleus muscle (primarily slow-twitch 
fibers).  Known differences in glucose regulation exist between the fiber types.  For 
example, GLUT4 protein level is greater in slow-twitch muscles compared to fast-twitch 
muscles (Henriksen et al. 1990), and the regulation of GLUT4 by ERα may also be 
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different depending on fiber type.  In addition, stress kinase proteins modulate glucose 
metabolism, and the level of stress kinases differ between fiber type, with fast-twitch 
muscles having greater stress kinase levels compared to slow-twitch muscles (Gupte et al. 
2008).  As stress kinase levels are higher in fast-twitch muscles, the ability of ERα to 
interact with NF-κB and alter GLUT4 levels may be greater in fast-twitch fibers.  Also, 
the lower amount of GLUT4 in fast-twitch muscles may allow GLUT4 to have room to 
be up-regulated.  Future studies are needed to determine the extent to which NF-κB and 
ERα interact to modulate GLUT4 levels.   
 
 
Localization of the ERs in skeletal muscle. 
 
While numerous studies show the presence of ERα and ERβ in skeletal muscle of 
various species including humans, mice, and rats (Kalbe et al. 2007), little is known about 
the specific localization of these receptors in skeletal muscle.  Knowing the localization 
of these proteins may predict the function of the receptors.  For example, while nuclear 
localization may suggest a role in gene regulation, membrane and cytoplasmic 
localization may suggest a role in cell signaling events.  To our knowledge, we have 
shown for the first time staining of ERα and ERβ in rat skeletal muscle.  ERα was 
localized throughout the cell, including the cytoplasm, nucleus, and membrane, in both 
the soleus and EDL (Figure 22A), and ERβ was localized to the nucleus in the soleus and 
throughout the cell in the EDL (Figure 22B).  Other studies show the presence of ERs in 
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various locations of skeletal muscle, with differences being attributed to species studied 
and antibodies used.  Immunohistochemical analyses in pig skeletal muscle using various 
ERα and ERβ antibodies show the presence of ERα either in the nucleus or undetected, 
albeit the presence of ERα shown via mRNA and Western blot; and ERβ was shown to 
have either a nuclear localization or both a nuclear and cytoplasmic localization 
depending on the source of the ERβ antibody (Kalbe et al. 2007).  In humans, staining for 
ERα and ERβ reveals the presence of the proteins in the nucleus (Wiik et al. 2009), yet 
ERα has also been undetected (Wiik et al. 2003).  In mice, ERα and ERβ was shown to 
be present in the nucleus (Barros et al. 2006b).  While determining the localization of the 
ERs in skeletal muscle is a new endeavor, clearly the source of the antibody plays a role 
in detection.  The location of the ERs in skeletal muscle may also differ by species.   
Localizing the ERs in the skeletal muscle may provide a useful tool for 
determining ERα–NF-κB interaction.  In an inactive state, NF-κB is bound by IκBα at a 
specific epitope on the p65 subunit of NF-κB.  To activate NF-κB, IκBα is 
phosphorylated, which signals its degradation by the proteosome.  The p65 epitope is 
now exposed, and a specific p65 antibody can detect this epitope, hence, detecting 
activated NF-κB (Kaltschmidt et al. 1994a; Kaltschmidt et al. 1994b; Kaltschmidt et al. 
1995).  Co-immunostaining of ERα and activated p65 may serve as a method to 
determine ERα–NF-κB interaction, both quantitatively and qualitatively (location in the 
cell).
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Figure 22: Immunohistochemistry of ERα and ERβ in female Sprague Dawley rats.  
The soleus and EDL muscles were removed from female Sprague Dawley rats an frozen 
in isopentane. 10 micron cross-sections were cut.  ERα is localized throughout the cell, 
including the cytoplasm, nucleus, and membrane, in both the soleus and EDL (A). ERβ 
is localized to the nucleus in the soleus and throughout the cell in the EDL (B). ERα and 
ERβ are shown in blue, dystrophin (membrane) is shown in green, and propidium iodide 
(nucleus; red) is shown merged with ERα/β (pink).  
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Phosphorylation of NF-κB p65 signals activation. 
 
Numerous studies report the ability of the p65 subunit of NF-κB to be 
phosphorylated.   p65 is phosphorylated at numerous residues, but we chose to focus on 
serine phosphorylation as this has been suggested to be important for its transcription 
activity (Hayden and Ghosh 2004).  Specifically, measuring phosphorylation of p65 on 
serine residues may indicate transcriptional activity and an association to GLUT4 
regulation.  Phosphorylation of p65 can occur in the cytoplasm or in the nucleus in 
response to stimuli.  TNF-α is a known stimulus for p65 phosphorylation on various 
serine residues (reviewed in (Viatour et al. 2005)).  TNF-α is a cytokine that is highly 
expressed in obese humans (Saghizadeh et al. 1996; Uysal et al. 1998), and obese humans 
with T2D have increased skeletal muscle NF-κB activation (Sriwijitkamol et al. 2006).  
Therefore, we chose to focus on serine residues which are phosphorylated via TNF-α 
stimulation.  Numerous research studies show that TNF-α-stimulated Ser536 
phosphorylation is required for nuclear translocation and enhances p65 transactivation 
potential (Sakurai et al. 1999; Jiang et al. 2003; O'Mahony et al. 2004).  Specifically, 
Zhong et al. demonstrated enhanced binding of p65 to DNA with Ser536 phosphorylation 
(Zhong et al. 1998).  Furthermore, inhibitory peptides corresponding to amino acids 525-
536 of p65 inhibit TNF-α-induced NF-κB activity (Takada et al. 2004).   
To explore the association between ERα activation and p65 regulation, we 
measured phosphorylation of p65 on Ser536 in the EDL muscles of rats treated with PPT.  
Rats treated with PPT showed increased GLUT4 protein in the EDL.  However, 
activation of p65 (as measured by phosphorylation of Ser536) did not decrease (Figure 
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23A).  A decrease in p65 phosphorylation would indicate less activation of p65, and p65 
is a negative modulator of GLUT4 transcription.  While we suspected that the p65 
phosphorylation may result from TNF-α stimulation (due to its up-regulation in obesity 
and T2D), no current evidence has established this association.  Therefore, we also 
measured phosphorylation of p65 on Ser468, which is not induced by TNF-α stimulation 
(Williams et al. 2008).  No differences in p65 Ser468 were measured between vehicle and 
PPT treated animals in the EDL muscle (Figure 23B).  
While we did not see any changes in p65 phosphorylation on Ser536 and Ser468, 
we cannot conclude whether or not p65 is altered with PPT treatment.  Numerous other 
phosphorylation sites may be modified as a result of ERα activation.  Particularly, 
numerous reports also suggest that Ser276 and Ser529 play an important role in 
regulating p65 transcriptional activity (reviewed in (Viatour et al. 2005)).  In addition, we 
measured p65 phosphorylation 24 hours following the final PPT treatment.  p65 
phosphorylation may occur in a time-dependent fashion to regulate GLUT4 levels, and 
optimal phosphorylation may occur prior to 24 hours.  Finally, measuring 
phosphorylation of p65 may not be the optimal technique to detect p65 activation.  While 
the literature supports the fact that p65 is phosphorylated upon activation, the standard 
technique of electrophoretic mobility shift assay (EMSA) would likely provide the best 
evidence for p65 activation.  
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Figure 23: No change in p-p65 in the EDL muscle from in PPT-treated 
rats.  Female Sprague Dawley rats were given subcutaneous injections of PPT 
(10 mg/kg) or vehicle for 3 days. Phosphorylation of p-65 was measured in the 
EDL muscle by Western blot analysis on residues Ser536 (A) and Ser468 (B) 
and normalized to total p65. Values are means + SE for 6 samples per group.   
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Using L6 cells to study ERα–NF-κB interaction. 
 
While evidence exists for the possibility of ERα to interact with NF-κB and 
regulate GLUT4 (see introduction), the details involving the interaction remain in its 
infancy.  To better guide researchers, a cell culture model may provide a better starting 
point.  A cell culture model would allow researchers to quickly manipulate the cells and 
make initial measurements regarding ERα–NF-κB interaction and GLUT4 regulation.  L6 
cells are a common skeletal muscle cell line originally isolated from rat thigh muscle.  
This cell line may provide a useful mean to study ERα, NF-κB, and GLUT4 interaction 
via treating the cells with various substances such as estrogen, specific estrogen receptor 
agonists/antagonists, NF-κB activators, and siRNA to name a few.  In fact, treating L6 
cells will TNF-α (a cytokine up-regulated in obesity and T2D) results in decreased 
GLUT4 protein (Figure 24).  Exploring how this decrease in GLUT4 protein is altered in 
the presence of additional substances may provide better evidence for ERα–NF-κB 
interaction and GLUT4 regulation.   
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Figure 24: TNFα treatment decreases GLUT4 protein in L6 cells.  L6 cells 
were treated with various concentrations of TNFα for 48 hours. GLUT4 protein 
levels were measured by Western blot analysis and normalized to tubulin. Values 
are means + SE for 3-6 samples per group; *P=0.066 vs. 0 (ng/mL). 
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Additional model for studying estrogen and metabolic regulation. 
 
 We have additional data suggesting that alternative models could be used to study 
the interaction between estrogen and metabolic regulation.  NADH cytochrome b(5) 
oxidoreductase (Ncb5or) is a flavoheme reductase involved in desaturation of fatty acids 
(Larade et al. 2008).  Ncb5or is widely expressed in various tissues and is located in the 
endoplasmic reticulum (Xie et al. 2004; Zhu et al. 2004).  The desaturation of fatty acids 
is an important step in triglyceride synthesis and fat storage.  Therefore, loss of Ncb5or 
results in lipoatrophy due to the inability to synthesize triglycerides and store fatty acids 
(Larade et al. 2008).  As a means of compensation, the fatty acids are metabolized in the 
endoplasmic reticulum, which results in overloading and endoplasmic reticulum stress-
induced lipotoxicity (Zhang et al. 2010).  The absence of Ncb5or also results in insulin-
deficient diabetes, resulting from a loss of pancreatic β cell function (Xie et al. 2004).  
When challenged with a high-fat diet (HFD), Ncb5or KO mice become diabetic at an 
even earlier age as metabolizing the increased amounts of fatty acids poses an extreme 
challenge (Zhu et al. unpublished data).  Interestingly, female Ncb5or KO mice become 
diabetic at a much later age, suggesting that the female sex hormones may provide 
protective benefits.  In fact, OVX in female Ncb5or KO mice advances the age of onset 
of diabetes compared to intact animals (Figure 25).  The mechanism of how estrogen may 
provide beneficial effects in protecting against the fatty acid overload remains unknown.   
However, estrogen is known to promote mitochondrial biogenesis and increase 
mitochondrial function.  When challenged with a HFD, female rats demonstrated higher 
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mitochondrial oxygen consumption and cytochrome c oxidase activity, and a better 
capacity to counteract the oxidative stress-induced insulin resistance by increasing 
expression of UCP3 in the skeletal muscle (Gomez-Perez et al. 2008).  The mechanism 
by which estrogen increases mitochondrial function has been explored on a genomic 
level.  Estrogen increases nuclear respiratory factor-1 (NRF-1) and up-regulates 
mitochondrial biogenesis via activation of ERα (Mattingly et al. 2008).  NRF-1 is a 
transcription factor that, along with PGC-1α, increases transcription of proteins involved 
in mitochondrial function, particularly Tfam (mtDNA maintenance factor) and TFB 
(mitochondrial transcription factor B) (Scarpulla 2006).  Tfam and TFB work to promote 
mitochondrial DNA transcription and mitochondrial biogenesis via acting as transcription 
factors (reviewed in (Klinge 2008).  An increase in mitochondrial biogenesis due to 
estrogen may better support fatty acid oxidation and decrease oxidative stress in female 
Ncb5or KO mice, providing a longer protection against the lipotoxicity observed in the 
male Ncb5or KO mice.  However, this theory remains speculative and more research is 
need.  Using Ncb5or KO mice may provide an additional model for studying the role of 
estrogen in metabolic regulation.  
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Figure 25: OVX in female Ncb5or KO mice advances the age of onset of diabetes.  Ovaries 
were removed from female Ncb5or KO mice (OVX) or left intact (sham) at 4 weeks of age. 
Blood glucose was monitored every 2 days. Diabetes was defined as a blood glucose level > 
200 mg/dL. Sham animals are shown in closed bars (N=6), and OVX animals are shown in 
open bars (N=8).  
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In sum, the data presented here constitute novel information regarding estrogen’s 
(specifically ERα) involvement in glucose metabolism and adipocyte regulation.  The 
signaling pathways and proteins regulated by ERα provide pertinent information for 
understanding skeletal muscle glucose metabolism, lipolysis, and lipogenesis.  
Furthermore, these data are new information to help explain the molecular differences 
between males and females with regard to fat storage and risk for insulin resistance and 
T2D.  
Whether or not activation of ERα can prevent and/or treat T2D remains an 
important question.  While we and others provide evidence suggesting ERα plays a role 
in insulin resistance, many other pathologies and physiological pathways contribute to 
T2D.  The extent to which ERα, and activation of ERα, contributes to insulin resistance 
has yet to be determined.  However, if this pathway would be pursued for potential drug 
treatments, tissue specific drug analogs are needed, as traditional estrogen therapy has 
already proven to produce greater health risks than the benefits obtained for decreasing 
the risk of insulin resistance.  Moreover, as drug development involves immense time, 
cost, and risk, exercise remains an established means by which T2D, and many of its 
consequences, can be reversed.  
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